Токсичность тяжелых металлов в клиническом и экологическом здравоохранении: источники, механизмы, диагностика и научно обоснованное управление ртутью, свинцом, кадмием и арсеником.

1. Introduction

Heavy metals, including mercury (Hg), lead (Pb), cadmium (Cd), and arsenic (As), are among the most intensively studied toxicants in environmental medicine and clinical toxicology. These elements and metalloids are naturally occurring substances distributed widely in the earth’s crust throughout ecological cycles, and some have been classified as one of the most toxic elements approved by the World Health Organization (WHO) as chemicals of major public health concern (see Figure 1 ) [ 1 , 2 ]. They originate mainly from natural sources, including volcanic activity, erosion, weathering of mineral deposits, and biological cycling through ecosystems [ 3 , 4 , 5 ].

During volcanic eruptions, a variety of metals are released into the atmosphere, including lead, mercury, and cadmium, which can remain in the atmosphere for extended periods, depending on the type and scale of the eruption [ 6 ]. Elemental mercury vapor is efficiently absorbed via the lungs and penetrates the central nervous system; inorganic salts concentrate in the kidney; organic methylmercury (MeHg), formed in aquatic food webs, is absorbed from the diet and avidly enters the fetal and adult brain.

Lead’s chemistry enables it to mimic calcium and bind to sulfhydryl and carboxyl groups, disrupting neurotransmission, heme synthesis, and bone metabolism [ 7 ].

Cadmium binds to metallothionein and progressively accumulates in the renal cortex, with biological half-lives measured in decades [ 8 ].

Arsenic occurs as trivalent arsenite and pentavalent arsenate, which undergo hepatic methylation to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA); chronic exposure—often via groundwater or rice—has multisystem consequences including dermatologic, vascular, metabolic, and oncologic outcomes [ 9 ].

Clinicians continue to encounter patients with exposures ranging from dramatic acute poisonings to subtle, chronic, low-level burdens that still confer measurable risk. Several previous reviews have summarized the environmental occurrence and toxic mechanisms of heavy metals, including broad overviews of arsenic, cadmium, chromium, mercury, and lead, as well as more focused mechanistic reviews [ 10 , 11 ]. However, these reviews do not fully integrate speciation-informed diagnosis, bedside decision pathways, stewardship of chelation, and cost-conscious prevention into a unified clinical and public health model.

What distinguishes the present review from prior reviews is its integrative, decision-oriented framework spanning the full pathway from exposure biology to bedside and public-health action. Rather than discussing heavy metal toxicity only in terms of toxic mechanisms or only as a clinical management problem, this review brings together mechanistic toxicology, species-specific biomarker interpretation and speciation, evidence-based clinical management, and the ethical and economic realities that shape real-world care. It also synthesizes more recent evidence on comparative effectiveness, stewardship of chelation, implementation barriers, equity, and emerging precision-toxicology approaches. By linking mercury, lead, cadmium, and arsenic within a single framework that integrates diagnosis, prevention, treatment, and policy, this review aims to offer a more practical and conceptually updated model for clinicians, toxicologists, and public health practitioners than reviews focused on isolated metals or narrower toxicological endpoints.

2. Sources and Environmental Fate

Mercury, lead, cadmium, and arsenic can also be naturally bound to other mineral compounds (see Table 1 ). For instance, Hg can bind to sulfur (e.g., cinnabar, HgS) and selenium (e.g., tiemannite, HgSe), as well as to other metals such as gold (Au) and silver (Ag) [ 12 ]. Pb can also bind to sulfur (e.g., galena, PbS) and others, such as sulfates (e.g., anglesite, PbSO 4 ) and carbonates (e.g., cerussite, PbCO 3 ), and is frequently associated with zinc (Zn) ores (e.g., sphalerite, ZnS), and is commonly associated with Pb, Iron (Fe), and Copper (Cu) ores [ 13 , 14 ].

Mercury is a globally distributed pollutant with important natural, anthropogenic, and re-emitted sources. Current estimates indicate that anthropogenic emissions to air are on the order of 2200 metric tons per year, whereas total global atmospheric mercury inputs are substantially higher when natural sources and re-emission from land and ocean reservoirs are included. Coal combustion is an important source, but artisanal and small-scale gold mining is generally considered the largest single anthropogenic source of mercury releases globally, and coal combustion accounts for roughly one-fifth rather than most of global anthropogenic atmospheric emissions. Mercury in the environment occurs as elemental, inorganic, and organic species, and its environmental behavior depends strongly on chemical form [ 18 , 19 ].

Elemental mercury (Hg 0 ) has been used in thermometers, switches, relays, some lighting products, dental amalgams, and other industrial or legacy applications. It is the only metal that is liquid at room temperature and can enter the atmosphere in vapor form. Organic mercury is dominated environmentally by methylmercury (CH 3 Hg + ), which bioaccumulates in aquatic food webs and is a major form in fish. Ethylmercury is relevant primarily as a metabolite of thimerosal, a preservative still used in some multi-dose vaccine vials, particularly certain influenza vaccines [ 20 ] In some cases, Hg is bound to airborne particles, which can be transported long before settling on the Earth’s surface. The interest in mercury toxicity has increased in modern science. However, it has been known as a neurotoxic substance for centuries, yet there remains controversy on the mechanism of interaction with biochemical processes.

Once elemental Hg is released into the air, it is transported over vast distances by wind patterns, where it undergoes complex atmospheric chemical reactions, such as oxidation, photo-oxidation, and particulate binding [ 15 ]. Oxidation of Hg occurs by atmospheric compounds such as ozone (O 3 ) and halogens (e.g., Cl). The process leads to the formation of oxidized Hg (Hg 2+ ), which is readily removed from the atmosphere due to its water solubility. The photo-oxidation of Hg can be promoted by ultraviolet light, increasing its potential for deposition in aquatic ecosystems [ 21 ].

Moreover, some oxidized Hg can bind to particulate matter, which can be later removed by gravity or precipitation [ 22 ]. Once Hg is transformed, it is removed from the atmosphere through wet and dry deposition. Wet deposition promotes Hg entry into ecosystems via surface waters or onto the land through rain, snow, fog, etc. [ 23 ]. Dry deposition promotes Hg to settle onto surfaces such as soil, water bodies, and vegetation without precipitation. However, Hg does not remain stationary in the environment due to Hg re-emission processes. Hg deposited on soil and water can be re-emitted into the atmosphere under certain conditions, such as high temperatures or changes in the chemical environment. When Hg is present in water bodies or soil, microbial activity or temperature changes can volatilize Hg back into the air as elemental Hg through evaporation [ 24 ]. Mercury deposited on plants can also be re-emitted in the atmosphere through foliar uptake and evapotranspiration [ 25 ]. However, anthropogenic activities have significantly altered the presence and concentration of these metals in the environment [ 6 ].

Lead (Pb) is known for its unique physicochemical properties, such as malleability, low electrical conductivity, softness, and slow dissolution in water. It has been used for centuries in many applications, including the manufacture of drinking water pipes and as an additive to gasoline [ 7 ]. Leaded petrol was one of the most significant sources of atmospheric lead in the 20th century. Lead compounds were added to gasoline as an anti-knock agent and were also incorporated into paint [ 26 ]. In developed countries, the use of lead is limited, but it remains in lead-containing products, such as gasoline, pigments, ceramics, and batteries [ 7 ]. Despite its beneficial contribution in many applications, lead is highly toxic and is one of the most widespread environmental health hazards. Because of its widespread use in many applications, it can enter the environment primarily through anthropogenic activities such as land application, mining, and smelting, via the recycling of waste materials and the combustion of fossil fuels [ 27 ]. Lead is also found in small quantities in cigarette smoke. The tobacco plant can accumulate lead from the soil, and when burned, small amounts of lead are released into the atmosphere [ 28 ].

Pb is introduced into the atmosphere during the weathering of rocks and minerals, where the natural breakdown of rocks and minerals takes place through physical and chemical weathering processes. Over time, trace amounts of lead are released into the atmosphere and become airborne [ 29 ]. Nowadays, Pb emissions exceed 100,000 metric tons per year from both natural and human activities. Though this is a relatively minor source compared to industrial activities, it contributes to local lead contamination, particularly in areas with high smoking rates [ 28 ]. In countries where lead-based paint is still in use, sanding, scraping, or burning these paints can release lead particles into the air. This is particularly common in older buildings and homes. Recycling lead-containing materials, such as lead-acid batteries or old lead-based products, can also contribute to atmospheric lead. Improper handling or processing in certain recycling facilities can release lead particles [ 30 , 31 , 32 ].

Coal contains trace amounts of cadmium, and when coal is burned for energy production, cadmium is released into the atmosphere as part of the emissions. Coal-fired power plants are significant sources of atmospheric cadmium [ 25 ]. Cadmium is also commonly found in ores that contain zinc, lead, and copper. Smelting and refining these metals often release cadmium as a byproduct. Smelters are significant sources of cadmium emissions, especially in regions with prevalent zinc production [ 16 ]. Historically, cadmium was used in paints as a pigment, particularly in yellow, red, and orange hues. Although its use has declined significantly due to health concerns, cadmium can still be found in older paints. Sanding or scraping old painted surfaces can release cadmium into the air, contributing to its presence in indoor and outdoor environments [ 33 ]. The extraction of metals such as zinc, lead, and copper often releases cadmium into the environment as a byproduct. During mining and ore processing, cadmium can be emitted into the atmosphere, water, and soil. Mining operations in regions with high cadmium concentrations in ores are a significant source of environmental cadmium pollution [ 34 ]. Cadmium is used in the production of rechargeable batteries. The production and disposal of these batteries can result in cadmium emissions, mainly when they are improperly disposed of or recycled. Cement manufacturing can release trace amounts of cadmium into the atmosphere, primarily when raw materials containing cadmium are used in production. This source is considered minor compared to others, but it can still contribute to localized cadmium pollution, particularly in areas with high cement production [ 16 ]. These activities release cadmium into the air, water, and soil. The primary industrial sources include coal combustion, metal smelting and refining, paint pigment production, and mining operations [ 18 , 30 ]. Anthropogenic activities are the primary contributors to cadmium pollution in the environment, with cadmium emissions exceeding 3000 metric tons annually [ 35 ].

Arsenic is widely present in the Earth’s crust and commonly co-occurs with iron (Fe) and sulfur (S) in sulfide ores, as well as with precious and base metals [ 36 ]. In nature, it is frequently bound within minerals such as arsenopyrite (FeAsS), realgar (As 4 S 4 ), orpiment (As 2 S 3 ), and iron arsenates like scorodite (FeAsO 4 ·2H 2 O); it also occurs in copper-arsenic sulfides (e.g., enargite and tennantite) and is often associated with gold (Au) and copper (Cu) deposits. These associations reflect hydrothermal and metamorphic processes that concentrate arsenic in polymetallic ore bodies. Globally, atmospheric arsenic emissions arise from both natural and anthropogenic sources [ 17 ]. Best current budgets indicate that anthropogenic emissions to the atmosphere (~17–38 × 10 9 g As·yr −1 ) are roughly double the natural background (~10–25 × 10 9 g As·yr −1 ), yielding a total on the order of 27–63 kilotons per year. Major natural contributors include volcanic/geothermal activity and wind-blown dust, whereas anthropogenic releases are dominated by coal combustion, non-ferrous metal smelting/roasting, and industrial processes.

3. Human Exposure and Risk Assessment

Human exposure to mercury (Hg), lead (Pb), cadmium (Cd), and arsenic (As) occurs through distinct but overlapping dietary, environmental, occupational, and household pathways [ 37 ]. Unlike essential trace elements such as iron, zinc, copper, manganese, molybdenum, cobalt, and selenium, these toxic metals and metalloids have no known beneficial physiologic role at environmentally relevant exposure levels. Their health effects depend on chemical form, dose, route, timing, co-exposures, and host susceptibility (see Table 2 ) [ 34 ].

For the general population, the main source of mercury exposure is dietary intake of methylmercury, primarily through fish and seafood. Methylmercury is the mercury species of greatest concern in food because it bioaccumulates in aquatic food webs and readily crosses both the placenta and the blood–brain barrier. Additional mercury exposure may occur in occupational settings, through accidental elemental mercury spills, and from some mercury-containing products. Dental amalgam contributes low-level mercury vapor exposure, but current evidence does not support routine removal of intact amalgam fillings in the general population [ 38 ]. The health effects of mercury depend strongly on speciation. Elemental mercury vapor is absorbed efficiently through the lungs and primarily affects the nervous system; inorganic mercury salts are more closely associated with renal toxicity; and methylmercury is particularly neurotoxic, especially during fetal and early-life development. Prenatal and early childhood methylmercury exposure has been associated with impaired cognition, attention, motor performance, and other neurodevelopmental outcomes [ 15 ].

Various studies have described molecular and cellular effects of organic Hg in the nervous system, which found that Hg 2+ may play a crucial role after exposure to CH 3 Hg + and CH 3 CH 2 Hg +, and have suggested that the existence of Hg 2+ in neurons results from the breakdown of organic Hg in glial cells, and that the levels of Hg 2+ were higher after exposure to CH 3 CH 2 Hg + [ 39 ]. Methylmercury exposure, particularly during pregnancy, infancy, and childhood, is associated with developmental and neurological effects [ 40 ]. Previous studies suggest that exposure to low levels of mercury may cause an increase in the risk of cardiovascular diseases, including hypertension and heart disease [ 41 , 42 ]. The exposure may also affect the immune system, leading to autoimmunity and increased susceptibility to infections by altering immune responses and causing inflammatory reactions [ 42 ]. All forms of mercury are one of the leading causes of adverse effects, including respiratory, immune, dermatologic, renal, reproductive, and developmental sequelae [ 40 ]. Researchers have also suspected that Hg is involved in the etiology of neurodegenerative diseases such as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson’s Disease (PD), or autism spectrum disorder (ASD) [ 40 ].

Lead is a potent neurotoxin that poses significant risks to the nervous system, with even minimal exposure having detrimental effects [ 43 ]. Although less common than ingestion or inhalation, dermal exposure to lead can occur in specific occupational settings where workers handle lead-containing materials. Despite the widely recognized health hazards, lead exposure remains a significant issue, especially for high-risk groups like children, pregnant women, and individuals employed in specific industries. The effects of lead exposure are well-established, and even low levels of exposure can cause a range of adverse health outcomes, including developmental delays, cognitive impairments, and neurological damage [ 27 ]. As lead-based paint deteriorates, it produces lead dust, which can settle on surfaces and become a source of exposure when children play on floors, touch contaminated surfaces, or put their hands in their mouths [ 25 , 44 ].

Children are particularly at risk, as low levels of lead exposure can lead to cognitive deficits, learning challenges, and behavioral disorders, including symptoms commonly associated with attention deficit hyperactivity disorder (ADHD) and other conduct-related conditions. For adults, chronic exposure to lead has been linked to memory impairments, diminished cognitive abilities, and a heightened likelihood of developing neurodegenerative disorders such as Alzheimer’s disease [ 45 ]. Lead has been shown to induce vascular damage and promote the development of atherosclerosis, a pathological condition characterized by arterial hardening, thereby elevating the risk of cardiovascular events such as myocardial infarction and cerebrovascular accidents [ 46 ].

Cadmium is classified as a human carcinogen and is harmful to various organs, particularly the kidneys, bones, and lungs [ 47 ]. Cadmium exposure can occur through various environmental and occupational routes, with sources including contaminated food, water, air, and tobacco smoke, as well as certain industrial activities [ 29 , 45 ]. Cadmium is absorbed by plants, mainly through contaminated soil, and accumulates in certain crops such as rice, leafy vegetables, and root vegetables, as well as seafood, especially shellfish and certain fish like tuna, due to contamination in aquatic environments [ 48 ].

Tobacco smoke is another significant source of cadmium exposure. Cadmium is present in tobacco plants because the metal accumulates in the plants’ soil [ 28 ]. Smoking results in direct inhalation of cadmium, which can lead to significant exposure, particularly in long-term smokers [ 33 ]. It is estimated that smokers have a higher body burden of cadmium compared to non-smokers [ 49 , 50 ]. Chronic exposure to cadmium primarily affects the kidneys, leading to kidney dysfunction and, in severe cases, kidney failure [ 47 ]. Prolonged exposure to cadmium can weaken bones, increasing the risk of fractures. This condition is known as Itai-Itai disease, which was first reported in Japan and is characterized by severe pain, bone fractures, and kidney dysfunction due to chronic cadmium exposure [ 46 , 51 ]. Chronic exposure to cadmium has been associated with increased blood pressure, which may contribute to the development of cardiovascular disease over time [ 52 ]. Cadmium exposure has also been shown to affect reproductive health, particularly in men, where it can lead to reduced sperm quality and fertility, and may also affect fetal development in pregnant women [ 53 , 54 , 55 ]. Table 3 summarizes the routes from absorption to excretion.

Risk is not uniformly distributed. Vulnerability is shaped by developmental stage (fetuses and children are most susceptible to neurotoxicity), physiologic state (pregnancy mobilizes maternal bone lead; CKD impairs excretion of Cd and Hg) [ 56 ], nutrition (iron deficiency increases Pb absorption; low calcium and zinc may exacerbate retention) [ 57 ], and co-exposures (tobacco smoke as a cadmium source, alcohol and medications affecting hepatic or renal handling) [ 58 ]. Social determinants—housing quality, access to safe water, food security, and occupational protections—modulate the likelihood of exposure and the capacity to mitigate it. Clinicians should couple medical history with a targeted exposure inventory that asks about housing age and renovations, water source and filtration, fish species and frequency, rice origin and preparation, workplace controls and PPE, recreational shooting, hand-to-mouth behaviors in children, cosmetics and folk remedies, and household contacts who may carry contaminants home from work.

Regulatory thresholds and health-based guidance vary by jurisdiction and are updated periodically. Importantly, no blood lead threshold has been identified as ‘safe’ for children, and both biomarker magnitude and clinical context should guide clinical action [ 59 ]. MeHg advisories are typically intake-based, translating to hair or blood benchmarks in surveillance [ 60 ].

Cadmium risk is often assessed using urine cadmium (normalized to creatinine) as a marker of body burden and as a tubular effect indicator (e.g., β2-microglobulin) [ 61 ].

Inorganic arsenic is best evaluated with urine speciation (iAs, MMA, DMA) to distinguish toxic species from non-toxic seafood arsenicals [ 62 ]. Equally crucial is risk communication: providing precise, culturally competent advice on safer fish choices, rice preparation to reduce arsenic, home lead hazard control (wet methods, HEPA vacuuming, interim controls), workplace hygiene (on-site laundering, changing areas), and smoking cessation. The objective is to reduce ongoing exposure before or alongside any medical intervention.

However, when humans experience high levels of metal in their bodies, chelation therapy is recommended. Chelation is only recommended when toxicity symptoms are present, and lab tests confirm toxic levels. There are specific concentrations of heavy metals for recommended chelation therapy (see Table 4 ) [ 63 , 64 ].

Instead, treatment decisions should integrate the metal species, biomarker level, symptoms, exposure context, and the likelihood that ongoing exposure can be stopped. For children with lead exposure, major clinical guidance supports chelation at blood lead concentrations of 45 µg/dL or higher, while recognizing that harm occurs well below this threshold. For mercury and arsenic, chelation may be appropriate in selected cases of acute or symptomatic poisoning, depending on speciation and timing. For cadmium, routine chelation is generally not recommended, because evidence of benefit is limited and some chelators may increase toxicity. Overall, risk assessment for heavy metal exposure should be species-aware, exposure-specific, and clinically contextualized. The most useful framework links source identification, biomarker interpretation, patient vulnerability, and practical exposure reduction strategies before or alongside any consideration of chelation.

4. Chelation Therapy–State of the Art

Chelation therapy, derived from the Greek word chele (“claw”), is a medical treatment used to remove heavy metals or other toxic substances from the body by binding them to chelating agents [ 65 ]. This treatment is primarily used to treat poisoning from metals such as mercury, lead, cadmium, and arsenic and to manage metal overload disorders, such as excess copper or iron. Chelation therapy works through the chemical properties of chelating agents, which contain specific functional groups, such as amines, thiols, or carboxyl groups, that can bind to metal ions. These interactions form stable, water-soluble complexes that neutralize the metal’s toxic effects. The process consists of three key stages: chelating agents bind to metal ions in the bloodstream or tissues, a stable complex forms between the agent and the metal, and the resulting complex is eliminated from the body through urine or feces. This process effectively decreases the toxic metal load and alleviates its harmful impact on the body.

Several endogenous and exogenous sulfur-containing compounds have metal-binding or redox-active properties, including alpha-lipoic acid (ALA), cysteine (Cys), and glutathione (GSH) (see Table 5 ). These are naturally occurring compounds in the human body, but they are not established primary chelators in routine clinical toxicology [ 67 , 68 , 69 , 70 ]. ALA is widely used as a nutritional supplements, especially in the US, in tablet, capsule, and liquid forms, and have been used as antioxidants to improve cellular glucose utilization in metabolic disorders and type-2 diabetes [ 69 ]. In 1966, Germany approved ALA as a drug for the treatment of diabetic neuropathy, and it is available as a non-prescription pharmaceutical [ 71 , 72 , 73 ]. Among the clinically established chelating agents are dimercaprol (BAL), dimercaptosuccinic acid (DMSA; succimer), calcium disodium EDTA, and dimercaptopropanesulfonic acid (DMPS), although approval status varies by country. In the United States, succimer, calcium disodium EDTA, and dimercaprol are FDA-approved for specific indications, whereas DMPS is not FDA-approved [ 74 , 75 ]. Chelation therapy is best understood as a targeted tool within a broader exposure-reduction strategy, not a panacea. The decision to chelate should follow a structured appraisal: (1) Which metal and species are implicated? (2) What is the clinical scenario—acute, subacute, or chronic? (3) Are there symptoms or objective organ injury? (4) What are the biomarker levels and their trajectory? (5) Are exposures controlled? (6) Do the anticipated benefits outweigh the risks for this patient in this setting? Across Hg, Pb, Cd, and As, indications, drug selection, dosing, and monitoring differ in clinically meaningful ways.

Alpha-lipoic acid (ALA) and its reduced form dihydrolipoic acid (DHLA) are sulfur-containing compounds with antioxidant and potential metal-binding properties. Their chemical behavior is influenced by carboxyl and thiol groups, and DHLA is generally the more reactive metal-binding form. Although ALA has been discussed as a possible adjunct in mercury, cadmium, and other metal toxicities, its clinical role remains limited by poor water solubility, variable bioavailability, and the fact that much of the evidence is mechanistic or experimental rather than based on established therapeutic use.

By contrast, DMSA and DMPS are the principal clinically relevant thiol chelators [ 76 , 77 , 78 ]. Both contain reactive sulfhydryl groups that form stable complexes with toxic metals, but they differ in solubility, elimination, and typical use: DMSA is widely used orally, especially for lead and selected mercury or arsenic exposures, whereas DMPS is more water-soluble and is used particularly for inorganic mercury and arsenic in settings where it is available [ 79 , 80 ]. In the United States, however, DMPS is not FDA-approved, and its use is more limited than that of succimer, dimercaprol, or calcium disodium EDTA.

Endogenous thiols such as L-cysteine and glutathione also contain sulfhydryl groups and play major roles in redox regulation, antioxidant defense, and cellular protection. However, their direct chelating effects are limited, so they should be regarded mainly as supportive biochemical defenses rather than primary therapeutic chelators [ 81 , 82 ]. Overall, the section supports a practical distinction between experimentally interesting sulfur-containing compounds, physiologic thiols with mainly protective roles, and evidence-based chelators that have clearer clinical applications [ 63 ].

Chelation efficacy reflects thermodynamics (stability constants), kinetics (on- and off-rates), ligand availability in target tissues, and continuous removal of the formed complex [ 91 , 92 ]. At equilibrium for a 1:1 complex M + L ⇌ ML, the stoichiometric stability constant is K 1 = [ML]/([M][L]) [ 93 ]. In vivo, conditional stability (Keff) depends on pH, competing ligands, and matrix effects; the chelatable fraction scales with Keff and the effective tissue concentration of L. Practically, therapy aims to keep complexation and excretion moving forward particularly through urinary clearance, rather than to reach equilibrium [ 94 ]. If a chelating agent contains several coordinating groups, the equilibrium behavior becomes more complex. In biological systems, the total concentrations of free L and M are often much lower than the total [L_t] and [M_t], and this is better described by the conditional or effective stability constant, K_eff. In theory, the chelatable metal fraction, [ML], is determined by K_eff and the tissue concentration [L_t] of the chelator. Efficient chelation therefore depends not only on affinity, but also on tolerability, tissue access, and continued elimination of the metal–ligand complex [ 95 ].

Regarding the chemical stability of a therapeutic chelate, it is worth noting that the initial assessment of a ligand’s (L) affinity for a toxic metal can be inferred using the Hard-Soft Acid-Base (HSAB) (see Table 6 ) [ 96 ]. Lewis defined an acid as an electron-pair acceptor and a base as an electron-pair donor. Based on this definition, positively charged metal ions are classified as acids because they function as electron acceptors. Forming a solvated (hydrated) metal ion creates a complex where water molecules act as electron donors, making H 2 O a Lewis base. Similarly, many oxygen-containing compounds also serve as Lewis bases.

In aqueous solutions, metal ions exist in solvated forms, and during chelation or complexation, water molecules in the solvation shell are replaced by another ligand (another Lewis base), forming a metal complex [ 96 ]. Lewis’s acids and bases can be categorized as “hard” or “soft.” Hard metal ions are generally small, highly charged, and less polarizable, whereas soft metal ions, such as Cu + , Hg 2+ , and Pt 2+ , are relatively larger and do not hold their valence electrons as tightly.

The stability of metal complexes and chelates depends on the hardness or softness of the metal ion and the ligand, as explained by Pearson in his Hard-Soft Acid-Base (HSAB) theory. Stable complexes generally result from interactions between hard and hard bases or soft acids and soft bases. For instance, oxygen-donor ligands form stable complexes with harder acids such as Fe(II) and Fe(III).

In contrast, soft ligands, such as those containing sulfur or selenium, form stable complexes with soft metals like mercury, cadmium, copper(I) and mercury species. Hard-hard complexes are predominantly electrostatic, as exemplified by the iron-oxygen bond, whereas soft-soft complexes exhibit more covalent bonding, such as the mercury-thiol bond.

Metals such as mercury and arsenic have a notably high electronegativity (approximately 2.0 on the Pauling scale), predisposing them to covalent bonding with carbon and sulfur. This property accounts for the abundance of organomercurial and organoarsenic compounds [ 97 ].

5. Toxicokinetics and Toxicodynamics

The ADME processes-absorption, distribution, metabolism, and excretion—vary significantly among Hg, Pb, Cd, and As, influencing biomarker choices and treatment strategies [ 98 ] (see Table 7 ). Elemental mercury vapor (Hg 0 ) is rapidly absorbed through the lungs and converted in tissues to inorganic mercury, which accumulates in the kidneys and CNS. In contrast, ingested inorganic salts (Hg 2+ ) are poorly absorbed in the gastrointestinal tract [ 99 ]. Methylmercury, bound to cysteine, is efficiently absorbed via amino acid transporters in the gut, crosses the blood–brain and placental barriers, undergoes enterohepatic recirculation, and builds up in neural tissues [ 100 ].

Lead absorption is greater in children compared to adults and rises with iron or calcium deficiency [ 101 ]. After initial distribution to soft tissues, most of the body’s lead burden is stored in bone, with half-lives spanning years to decades and the potential for physiological remobilization during pregnancy, lactation, osteoporosis, and hyperthyroidism [ 102 ].

Cadmium’s gastrointestinal (GI) absorption is generally modest but increases during deficiency states and through shared metal transporters [ 103 ]. Its complexation with metallothionein promotes accumulation in the renal cortex and results in prolonged half-lives, explaining why urinary cadmium remains detectable long after exposure has decreased [ 52 ].

Inorganic arsenic is absorbed efficiently, then methylated in the liver to MMA and DMA, and mainly excreted via urine [ 104 ]. Variations among individuals in methylation capacity, such as higher levels of MMA, are linked to increased susceptibility to arsenic toxicity [ 105 ].

Toxicodynamics involve common pathways such as thiol binding, oxidative stress, and mitochondrial dysfunction, but they also include specific targets for each agent [ 106 ]. Lead disrupts voltage-gated calcium channels and heme synthesis by inhibiting δ-aminolevulinic acid dehydratase, leading to neurocognitive issues and anemia [ 107 ].

Cadmium affects redox balance, damages proximal tubular function, and promotes osteotoxicity by disrupting calcium and vitamin D metabolism [ 108 ]. Mercury harms neurons and podocytes through oxidative and immune pathways, with methylmercury (MeHg) being especially neurotropic [ 91 ].

Arsenic, particularly in its trivalent form, binds to enzyme complexes dependent on lipoic acid and interferes with signal transduction, angiogenesis, and DNA repair, explaining its vascular and carcinogenic effects [ 92 ]. Understanding these mechanisms helps in interpreting biomarkers and developing strategies to support nutrient status and reduce iatrogenic risks during treatment [ 109 ].

6. Clinical Manifestations

Clinical signs depend on the dose, exposure duration, species involved, as well as the patient’s age and health conditions [ 110 ]. Neurological symptoms can range from slight decreases in executive functioning and attention in children with low-level lead exposure [ 59 ] to more serious effects like peripheral neuropathy, tremors, and neuropsychiatric issues associated with mercury [ 111 ]. In utero methylmercury exposure is linked to delayed neurodevelopment, which can take years to detect [ 112 ]. Arsenic exposure presents with skin changes such as palmar-plantar hyperkeratosis and raindrop hyperpigmentation, alongside vascular problems, peripheral neuropathy, and higher risks of skin, bladder, and lung cancers in people exposed over time [ 113 ]. Cadmium primarily causes kidney damage, particularly in the proximal tubules, leading to proteinuria and progressive chronic kidney disease. It also affects bones, causing osteopenia and fractures in severe cases [ 114 ].

Acute cases require quick stabilization and focused history-taking (see Table 8 ). In cases of inorganic arsenic ingestion, symptoms often include severe gastrointestinal issues, dehydration, low blood pressure, QT interval prolongation, and nerve damage [ 115 ]. Lead encephalopathy manifests with vomiting, ataxia, seizures, and mental changes; these require urgent chelation therapy and source removal [ 116 ]. Inhalation of elemental mercury vapor can cause pneumonitis and later neurological problems; early supportive treatment and removing the patient from exposure are essential [ 117 ]. Subacute and chronic cases are more variable: symptoms like fatigue, headache, cognitive difficulties, tingling, mild anemia, hypertension, reduced eGFR, and hormonal changes [ 110 ]. A detailed exposure history, symptom review related to specific systems, targeted physical exam (checking skin, nervous system, and the characteristic ‘blue-black’ Burton line on gums in lead poisoning), and basic laboratory tests are vital for guiding further testing [ 118 ].

Recent real-world case reports and outbreaks further illustrate how heavy metal intoxication continues to present through household, occupational, environmental, medicinal, and behavioral exposure pathways, often with nonspecific early manifestations that delay diagnosis (see Table 9 ).

Differential diagnosis covers a wide range (see Table 10 ). When evaluating neuropathy and cognitive issues, consider conditions like diabetes, thyroid problems, B12 deficiency, medication side effects, sleep disorders, and depression [ 132 ]. For renal issues, review NSAID usage, contrast exposure, autoimmune diseases, and obstructive uropathy [ 133 ]. To distinguish anemia causes, differentiate between iron deficiency, chronic disease, hemolysis, and sideroblastic conditions [ 134 ]. Indicators of metal exposure include relevant exposure history, combined neurological and kidney symptoms, skin signs such as in arsenic poisoning, and biomarkers that help identify specific metals [ 110 ].

7. Clinically Relevant Toxic Dose Ranges and Thresholds

Clinically relevant toxic thresholds help translate exposure and biomonitoring results into decisions, but they should be interpreted as action-oriented reference values rather than absolute cutoffs (see Table 11 ). Toxicity varies according to chemical species, route, duration, age, nutritional status, pregnancy, comorbidity, and symptom burden. For mercury and arsenic, speciation is especially important because organic and inorganic forms differ substantially in toxicokinetics and clinical implications. For lead, no safe pediatric blood concentration has been established, so even relatively low values may justify exposure investigation and follow-up. For cadmium, chronic renal risk may occur at lower urinary levels than older regulatory models suggested. Table 11 summarizes clinically relevant acute and chronic thresholds for Hg, Pb, Cd, and As together with the preferred matrix and major interpretive caveats.

8. Diagnostics and Monitoring

The diagnostic approach starts with an exposure history and moves to specific biomarkers selected to address a particular clinical question such as recent exposure, body burden, or effect [ 138 ] (see Table 12 ). For lead, venous blood lead level (BLL) remains the main test for recent exposure and risk assessment, and capillary results must be confirmed by venous testing to prevent false positives caused by surface contamination [ 139 ]. For mercury, whole-blood mercury indicates recent methylmercury (MeHg) and elemental exposure, while urine mercury provides a better measure of inorganic forms and renal burden [ 140 ]. For cadmium, urine cadmium (adjusted for creatinine) acts as a marker of body burden, supplemented by low-molecular-weight protein markers (e.g., β2-microglobulin) to assess tubular effect [ 141 ]. For arsenic, total urine arsenic is not meaningful without speciation, laboratories should report inorganic arsenic (iAs), monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA) separately and advise patients to avoid seafood for at least 48 h before testing to reduce arsenobetaine interference [ 142 , 143 ].

Speciation becomes clinically significant when it influences management decisions. Differentiating between MeHg and inorganic Hg helps determine whether dietary advice or workplace safety measures are more urgent [ 140 ]. A high MMA-to-DMA ratio for arsenic indicates reduced methylation ability and a potentially increased risk [ 144 , 145 ]. Bone lead levels measured by K-XRF serve as a research tool indicating long-term exposure, which can aid in epidemiological studies, though they are rarely decisive in individual clinical assessments [ 146 ]. Hair analysis for MeHg is suitable when sampling and cleaning protocols are strict; however, results should be interpreted considering local fish consumption habits and cosmetic treatments [ 140 ].

Different biological matrices answer different clinical questions, and no single specimen is universally superior for all metals or exposure scenarios. Blood is generally most useful for recent or ongoing exposure, particularly for lead and some forms of mercury. Urine is often preferred for inorganic mercury, cadmium body burden, and arsenic speciation, especially when renal handling and recent exposure are relevant. Hair can provide a longer-term exposure signal, especially for methylmercury, but is more vulnerable to external contamination and requires careful sampling and interpretation. Sweat has limited validated clinical utility and should not be used as a primary diagnostic matrix for toxic metal exposure. A comparative understanding of matrix strengths and limitations can improve test selection, reduce misinterpretation, and better align laboratory findings with clinical decisions.

Pitfalls include relying on unvalidated ‘provoked’ urine tests after chelator challenge, which can nonspecifically increase urinary metal excretion and lead to potential misclassification of exposure [ 148 ] (see Table 13 ). Urine test results should be adjusted for creatinine levels, and clinicians must consider hydration status [ 138 ]. Pre-analytical factors such as tube type, contamination prevention, and chain-of-custody procedures in cases with occupational or legal consequences are vital to prevent misinterpretation [ 149 , 150 ]. Ultimately, clinicians should interpret biomarker results alongside decision thresholds that reflect symptoms, ongoing exposure, and patient preferences [ 151 ]. Testing without a clear management plan may cause unnecessary anxiety and treatment [ 152 ].

9. Supportive and Preventive Management of Toxic Metal Exposure: Source Control, Nutrition, and Rational Use of Chelation

Managing exposure to mercury (Hg), lead (Pb), cadmium (Cd), and arsenic (As) starts with understanding that removing the source and providing careful supportive care often leads to better outcomes, and poses fewer risks than pharmacological treatments [ 110 , 155 ] (see Figure 2 ). The key steps include: (1) confirming exposure and its circumstances, (2) reducing or stopping ongoing exposure, (3) addressing host factors such as nutrition, other health conditions, and medications, (4) promptly treating acute complications, and (5) consulting chelation therapy only if evidence indicates that benefits outweigh potential harms. Since these toxins affect multiple organs and often occur together, clinicians should plan a coordinated approach involving individual, household, workplace, and public health measures.

Source control is the anchor. For the home, practical steps include identifying and stabilizing deteriorating lead-based paint (use of wet methods rather than dry sanding; high-efficiency particulate air [HEPA] vacuuming, interim controls, professional abatement when indicated), flushing stagnant plumbing and replacing lead service lines or leaded brass fixtures where feasible, using certified point-of-use filters for drinking and cooking water, and addressing imported ceramics, spices, cosmetics, or traditional remedies implicated in outbreaks [ 156 ]. For diet, pair exposure reduction with nutrition: correct iron deficiency (reduces gastrointestinal absorption of lead), ensure adequate calcium and zinc intake, guide safer fish choices and portion sizes to minimize methylmercury while maintaining omega-3 benefits, and discuss rice sourcing and preparation techniques (e.g., rinse/soak, excess-water cooking) for arsenic [ 157 , 158 , 159 , 160 ]. For tobacco exposure, smoking cessation is a cadmium reduction strategy with significant co-benefits [ 161 ]. At work, hierarchy-of-controls thinking applies to eliminate or substitute metals where possible, implement engineering controls (local exhaust, process enclosure, wet methods), administrative controls (rotation, hygiene policies), and personal protective equipment (fit-tested respirators, gloves), provide on-site showers and changing areas to prevent ‘take-home’ contamination [ 110 ].

Acute management begins with ABCs (airway, breathing, circulation), decontamination when necessary, and early contact with a regional poison center or toxicologist [ 117 ]. For acute inhalational exposure to Hg vapor, remove the patient from the source, administer supplemental oxygen, consider corticosteroids for chemical pneumonitis on a case-by-case basis, and observe for delayed neuropsychiatric effects [ 162 ]. In cases of acute inorganic arsenic ingestion, provide aggressive fluid resuscitation, antiemetics, electrolyte repletion (notably potassium and magnesium in diarrhea or QT interval prolongation), cardiac monitoring, and consider chelation early [ 163 ]. Acute lead encephalopathy is a neurological emergency requiring management of intracranial pressure, seizure control, and prompt initiation of guideline-based chelation combined with environmental assessment [ 164 ]. For suspected mixed metal exposures, such as e-waste or battery recycling, expand the diagnostic scope and avoid focusing solely on one analyte [ 75 ].

Supportive and preventive measures include targeted laboratory and clinical monitoring [ 110 ]. Establish baseline levels for complete blood count, electrolytes, renal and hepatic function, and urinalysis; consider adding β2-microglobulin or retinol-binding protein if cadmium nephrotoxicity is suspected [ 108 ]. Schedule repeat testing based on the expected kinetic timelines: weeks to months for mercury and lead, months to years for cadmium, and days to weeks for arsenic due to its shorter biological half-life but ongoing exposure in endemic areas [ 110 ]. Link each lab test to a specific clinical decision, for example, if blood lead remains high despite interventions, escalate home remediation efforts; if urinary inorganic mercury levels decline with mild symptoms, focus on source control rather than chelation [ 110 ].

Nutritional and pharmacologic adjuncts require careful framing. In iron-deficient children, iron repletion decreases lead absorption and supports hematologic health [ 165 ]. Adequate intake of calcium and zinc can lessen intestinal absorption and prevent displacement from key enzymes. Selenium can influence mercury toxicity on a biochemical level but is not a chelator and should not be relied upon as a standalone detox method [ 87 ]. Antioxidants like alpha-lipoic acid (ALA) and glutathione (GSH) are involved in redox homeostasis but lack proven clinical efficacy as primary treatments for heavy-metal poisoning. They may be used as nutritional support in certain cases, but it is important to clarify they do not replace chelation when necessary. Patients should be advised honestly about internet-promoted detox regimens, highlighting the importance of evidence, safety, and reducing exposure [ 148 ].

Special populations need customized plans. During pregnancy, focus on prevention and exposure control; avoid chelation unless maternal toxicity is life-threatening and specialist advice is sought [ 164 ]. In pediatrics, due to developmental sensitivity and narrow therapeutic margins, accurate dosing and close monitoring are essential when administering any medication, collaborate with public health for home hazard management and caregiver training [ 153 ]. In chronic kidney disease, reduced excretory function raises the risk of chelator–metal complex buildup and kidney damage; modify doses accordingly, avoid nephrotoxic drugs, and consult nephrology. For workers, management involves medical removal when required, regular biological monitoring, and collaboration with employers on engineering and administrative controls; record fit testing and training. Engagement of mental health, social work, and community health professionals is crucial for effective advice and action consult them early.

Risk communication serves as a standalone intervention. Effective counseling should be specific such as identifying which fish are safer in your area, how to cook rice properly, and which renovation practices to avoid, while also being culturally acceptable and feasible with the family’s available resources. Using written materials in the patient’s language, including pictures of fish species or water filters, and coordinating with community programs (like lead-safe home initiatives or well testing) can enhance adherence. For households with children, address behaviors like hand-to-mouth activity, frequent wet-mopping of floors and window sills, and washing toys and hands [ 156 ]. For shooters, promote range hygiene, such as avoiding food on the line, using dedicated shoes and clothing, and laundering immediately. Ensure clinical messaging aligns with public health agencies to prevent conflicting guidance.

Finally, develop a monitoring and follow-up plan that accounts for biomarker kinetics and the progression of health effects [ 110 ] (see Table 14 ). For example, after removing a high-mercury fish from the diet, reassess hair or blood mercury levels after 3–4 months [ 166 ]. Following lead hazard control, monitor venous blood lead levels at intervals suited to the baseline level and age [ 153 ]. For cadmium-related tubular proteinuria, check urinary markers twice a year. In endemic regions, combine serial urinary speciation with water remediation verification. Conclude by explaining results clearly and connecting them to future steps. The main goal of supportive and preventive care is to avoid chelation therapy unless necessary, reserving such drugs for patients most likely to benefit [ 148 ].

10. Comparative Effectiveness and Health Economics

Comparative effectiveness analysis aids clinicians in selecting suitable chelators and recognizing when chelation may not lead to better outcomes [ 110 ]. The supporting evidence varies depending on the metal involved and the specific clinical situation. For lead, both randomized and observational studies consistently show that chelators reduce blood lead levels; however, neurodevelopmental improvements in asymptomatic children with moderate elevations have not been seen with succimer, despite significant reductions in blood levels [ 168 ] (see Table 15 ). This disconnects between changes in biomarkers and functional outcomes highlights a key principle: factors like timing, age, ongoing exposure, and initial injury influence whether lowering the biomarker results in tangible clinical benefits [ 169 ].

In adults with occupational lead exposure and symptoms, or with very high blood lead levels, chelation combined with removal from exposure can enhance hematologic and neurological health; in these cases, improvements in both biomarkers and clinical conditions typically occur when exposure is effectively controlled [ 168 ].

For mercury, the strongest evidence for chelation concerns inorganic forms with renal involvement [ 170 ]. DMPS and DMSA increase urinary excretion and can improve symptoms when exposure ceases; evidence for methylmercury is weaker, with benefits most plausible at high levels and with persistent symptoms after dietary cessation [ 85 ]. For arsenic, chelation clearly improves outcomes in acute inorganic poisoning, especially when initiated early; beyond the acute setting, benefits are less clear, and prevention dominates [ 170 ]. For cadmium, the lack of convincing benefit and renal risks tilt the calculus away from chelation in chronic exposures; supportive renal and bone care with exposure reduction is the standard [ 110 ].

Head-to-head comparisons are limited but provide useful insights. DMSA and DMPS both mobilize inorganic mercury and arsenic; DMPS might have practical benefits, such as availability in IV form and strong affinity for mercury, especially in severe cases [ 168 ]. Conversely, DMSA’s oral tolerability and pediatric safety data are advantages [ 83 ]. For lead, DMSA is generally preferred orally in cases without encephalopathy, while CaNa 2 EDTA (±BAL) is reserved for severe cases [ 168 ]. BAL remains a rescue therapy, effective but with limitations due to side effects and logistical challenges [ 79 ]. No chelator has proven superior in improving functional outcomes for low-level, chronic exposure without symptoms, compared to thorough source removal and supportive care [ 169 ].

Health economics considers these decisions at the system level [ 171 ]. The expense of chelators is often overshadowed by the costs of hospital care (for BAL and CaNa 2 EDTA), lab tests, clinic visits, and lost productivity [ 172 ]. When chelation does not improve functional outcomes, it is unlikely to be cost-effective compared to aggressive exposure reduction, environmental cleanup, and nutritional strategies [ 173 ]. However, in true emergencies, such as lead encephalopathy, acute arsenic poisoning, or severe inorganic mercury exposure with renal failure, chelation prevents morbidity and death and proves highly cost-effective despite short-term costs [ 170 ]. This approach supports a tiered strategy: invest in prevention and remediation for the many, use chelation only for the few with clear indications, and provide rapid access for the rare, life-threatening cases [ 174 ].

Access and implementation are crucial [ 175 ]. In low- and middle-income countries and underserved communities, challenges include shortages of chelators like BAL and CaNa 2 EDTA, cold-chain or compounding needs, limited laboratory capacity for speciation, and patient-related costs [ 175 ]. Policies that subsidize certified water filters, lead service line replacements, and safer renovation practices often yield higher population health benefits per dollar compared to expanding chelation options [ 176 ]. When chelation is necessary, using standardized order sets, dosing calculators, and checklists helps minimize errors and waste [ 177 ]. Training clinicians to identify red flags such as encephalopathy, GI shock in arsenic poisoning, or renal injury from inorganic mercury can shorten the time to treatment and lead to better health outcomes [ 178 ].

Stewardship combines clinical ethics and economics [ 179 ]. An effective program rests on three pillars: (1) diagnostic accuracy, confirming the species, verifying ongoing exposure, and avoiding provocation tests; (2) treatment discipline, using clear indications, weight-based dosing, lab monitoring, and stopping rules; and (3) prevention as a priority [ 148 ], documenting source control, notifying public health, and protecting workers. Quality metrics may include the time from diagnosis to exposure mitigation, the percentage of chelation episodes meeting strict criteria, adverse drug event rates, and patient-reported outcomes like symptom scores and function at follow-up [ 180 ]. Integrating these metrics into electronic health records and public-health reports supports accountability and program evaluation [ 181 ].

Decision-support tools can convert comparative evidence into practical bedside decisions [ 182 ]. Simple algorithms, based on factors like metal levels, biomarker ranges, symptom clusters, or pregnancy/CKD status, help determine whether to (a) increase exposure control and monitoring, (b) start outpatient oral chelation with close follow-up, or (c) escalate to inpatient parenteral therapy [ 183 ]. Cost-aware versions of these algorithms can factor in local drug availability, lab access, and social support systems [ 184 ]. When clinicians and public health partners use consistent pathways and terminology, the healthcare system can efficiently direct patients to the appropriate intervention at the optimal time, thereby maximizing health benefits relative to costs [ 185 ].

11. Emerging and Adjacent Therapies

Emerging and related therapies aim to address two major limitations of current approaches: (1) the limited selectivity of chelators that can remove essential metals and lead to side effects, and (2) the weak connection between molecular diversity (such as speciation, host genetics, and microbiome) and personalized treatment [ 189 ]. The research field is vibrant across materials science, pharmacology, and systems toxicology, with several themes expected to shape clinical practices in the coming decade [ 190 ].

Next-generation chelators and delivery systems emphasize specificity, tissue targeting, and safety [ 190 ]. Polymeric and nanoparticle scaffolds can display multiple thiol, dithiol, or hydroxamate groups at precise intervals, increasing affinity for target metals while reducing unintended binding to zinc and copper [ 191 ]. Ligands can be adjusted to prefer certain oxidation states (such as Hg 2+ versus organomercury) or to operate effectively across physiological pH ranges [ 192 ]. Encapsulation methods, including liposomes, polymeric micelles, or dendrimers, can direct chelators to renal or hepatic tissues, lowering systemic exposure and potentially enhancing the therapeutic window [ 84 ]. Prodrugs that activate in oxidizing or acidified environments (like inflamed proximal tubules) provide localized activity with reduced systemic toxicity [ 193 ]. Although still in early stages, these approaches indicate that future chelation therapy may resemble targeted oncology, precise, compartmentalized, and accompanied by biomarkers [ 194 ].

Biological and catalytic methods utilize nature’s innate metal management systems [ 195 ]. Engineered metallothioneins, heme-oxygenase mimetics, or peptide sequences with high affinity for Hg, Pb, or Cd can bind metals for removal or aid in transfer to external chelators [ 195 ]. Research is also ongoing into catalysts that transform more toxic metal species into forms easier to eliminate, such as organomercury demethylation or arsenic oxidation [ 196 ]. Additionally, microbiome-based approaches aim to decrease intestinal absorption or convert metals into less bioavailable complexes [ 197 ]. While microbiome modulation through fecal or oral methods is still emerging, it is promising due to the gut’s key role in MeHg uptake and enterohepatic cycling [ 198 ].

Precision toxicology combines genomics, epigenomics, and metabolomics with exposure science to assess risk and customize treatment [ 198 ]. Variations in metallothionein genes, transporters, or enzymes like AS3MT that are involved in arsenic methylation influence body burdens and health outcomes; similarly, differences in calcium and iron metabolism affect lead kinetics [ 36 ]. In clinical practice, this could lead to risk-based intervention thresholds or choosing between DMPS and DMSA, depending on which is predicted to yield a better response or fewer side effects for a patient [ 36 ]. Metabolomic profiles may also help distinguish symptomatic from asymptomatic individuals with similar biomarker levels, indicating who might benefit from chelation therapy rather than just intensified prevention [ 199 ].

Extracorporeal and device-based therapies are specialized but important options [ 200 ]. Intermittent hemodialysis and hemoperfusion play a role in severe inorganic mercury or arsenic poisoning with renal failure, acting as supportive measures until chelation and source control are effective [ 201 ]. Future devices might feature metal-selective adsorbents or resin cartridges tailored to specific speciation profiles, enhancing the removal of chelator–metal complexes or free ions during critical short periods [ 202 ]. However, practicality remains a challenge: these methods are resource-intensive and compete with more scalable prevention approaches [ 203 ].

Adjacency is important: interventions beyond chelators can effectively reduce risk [ 204 ]. Adequate selenium levels may help buffer some mercury effects at the enzyme level; the status of iron, calcium, and zinc influences the intestinal absorption of lead and cadmium [ 205 ]. Ongoing development in redox modulation drugs shows promise, though clinical outcomes still need validation [ 195 ]. In public health, innovations such as point-of-use filtration (like arsenic-selective media and lead-capturing cartridges) and rapid field testing for speciation could revolutionize detection and prevention, lessening reliance on downstream treatments [ 206 ]. Digital health tools that monitor fish consumption, rice sources, and water filter upkeep can help turn advice into lasting behavior change across populations [ 203 ].

Translation challenges are expected: demonstrating not only biomarker changes but also concrete health outcomes; maintaining manufacturing quality and stability for complex biologics and nanomaterials; aligning pricing and reimbursement with public health advantages; and ensuring equitable access so that high-risk communities receive early, not delayed, access [ 206 ]. Despite these hurdles, the outlook is optimistic: more targeted and safer chelation therapies combined with molecular and environmental precision, integrated into a prevention-focused ecosystem [ 197 ].

12. Guidelines and Practice Pathways

Guidelines and practice pathways convert scattered evidence into clear, actionable steps for clinicians, public health workers, and patients [ 153 ]. Since Hg, Pb, Cd, and As vary in forms, behavior, and clinical effects, these pathways must be specific to each metal while maintaining a common framework: screen if risk exists, confirm with the appropriate test, control the source, treat the patient, focusing on individual needs rather than just numbers, and set measurable follow-up goals [ 207 ]. A good pathway is concise enough to display on a clinic wall yet detailed enough to address special populations and escalation procedures.

A standardized clinical algorithm starts with assessing exposure risks. In pediatrics, screen for lead exposure by considering housing age, renovation history, and caregiver occupational exposures; perform a venous BLL if there is identified risk or if required by local guidelines [ 153 ]. To evaluate methylmercury risk, check fish species and how often they are consumed; for inorganic mercury, inquire about occupational environments such as mining, dentistry, or artisanal gold work, as well as spills and hobbies [ 208 ]. For cadmium, ask about tobacco use and occupational history related to batteries or smelting; for arsenic, investigating well water sources, residence in endemic areas, and rice intake [ 209 ]. When a risk is plausible, order specific tests such as venous BLL; whole blood or urine mercury depending on suspected species; urine cadmium with creatinine adjustment and markers of tubular damage; and urine arsenic speciation after 48–72 h of avoiding seafood.

Decision nodes should clearly specify action thresholds and priorities. If BLL is significantly elevated or symptoms are evident, start chelation according to protocol (DMSA for moderate cases, BAL + CaNa 2 EDTA for encephalopathy) while accelerating home inspection and remediation. For elevated whole-blood mercury levels alongside a diet high in MeHg, focus on counseling to stop consuming high-mercury fish, consider hair testing to track declines, and reserve chelation for severe or ongoing cases [ 170 ]. When urine inorganic mercury is high with signs of kidney involvement, select DMPS or DMSA and monitor renal function. If urine arsenic shows high inorganic fractions and MMA/DMA ratios indicating poor methylation, combine water remediation with chelation for acute toxicity; otherwise, prioritize prevention and cardiovascular risk management [ 154 ]. For elevated urine cadmium and tubular proteins, avoid chelation, but increase exposure controls and address CKD risk factors such as blood pressure, blood sugar, and bone health [ 209 ].

Practice pathways should include safety checks. Before chelation therapy, obtain baseline CBC, CMP, urinalysis, and pregnancy testing where relevant; screen for G6PD deficiency if BAL is considered; confirm that CaNa 2 EDTA (not disodium EDTA) is ordered to prevent iatrogenic hypocalcemia [ 210 ]. Define laboratory monitoring intervals (such as weekly during parenteral treatment, after each oral cycle, and then every 1–3 months) and clinical assessments (for rash, mucositis, transaminitis, neuropathy) [ 170 ]. Set stopping criteria: discontinue when biomarkers reach target levels, symptoms resolve, and source control is confirmed; reassess if rebound occurs, with focus on bone lead mobilization and unresolved exposures.

Operationalization is crucial. Develop EHR order sets that automatically select appropriate tubes, tests (including speciation), and timing. Include patient instructions such as “avoid seafood for 72 h before urine arsenic speciation.” Establish referral pathways to public health inspectors, housing agencies, occupational health, and legal aid, especially when landlord or employer cooperation is limited [ 153 ]. For pediatric cases, it includes developmental screening and supportive services. For occupational cases, ensure pathways comply with regulatory standards for medical removal, return-to-work criteria, and periodic monitoring [ 211 ]. Clearly define roles: primary care handles screening and counseling; toxicology consults oversee chelation decisions; nephrology monitors CKD; obstetrics manages pregnancy care; and public health coordinates environmental interventions [ 153 ].

Special populations require dedicated sections in the pathway. Pregnancy: focus on prevention, delay chelation unless maternal health issues justify it, and involve maternal–fetal medicine early [ 164 ]. Pediatrics: adopt low thresholds for environmental interventions, ensure careful dosing, and conduct frequent follow-ups [ 153 ]. CKD: adjust doses, select agents with safer renal profiles, avoid nephrotoxins, and coordinate care with dialysis if needed [ 170 ]. Resource-limited communities: offer practical alternatives like subsidized filters, lists of safer fish relevant to local markets, and affordable rice preparation methods, using community health workers to help overcome language barriers and build trust [ 212 ].

Finally, practice pathways should be dynamic documents. Set a regular review schedule (e.g., yearly) to update thresholds, lab techniques, and drug options; monitor metrics such as time to source control, appropriate chelation rate, adverse events, and patient feedback; and include input from patients and frontline clinicians [ 209 ]. A successful pathway not only decreases variation but also improves care, accelerates the time to appropriate action, and prevents both undertreatment and overtreatment [ 169 ].

13. Ethics, Misinformation, and Med-Legal Considerations

Ethics, misinformation, and medico-legal issues are integral to heavy-metal practice, not peripheral [ 213 ]. The decisions regarding screening, testing, and chelation occur amidst a landscape filled with internet claims, commercial “detox” products, and legal pressures, which can influence both patients and clinicians in conflicting ways. Ethical practice demands transparency about the evidence limits, a commitment to do no harm, respect for patient autonomy, and fairness for communities disproportionately affected by exposure [ 214 ].

The primary ethical issue is to prevent iatrogenic harm caused by unnecessary testing and treatment [ 215 ]. Non-validated “provoked” urine tests can show high results that stem from pharmacologic activation rather than true body burden [ 148 ]. Using these results to justify chelation can expose patients to drug risks without proven benefit [ 213 ]. Ethically, clinicians should order tests that address specific clinical questions and have validated interpretation methods [ 149 ]. If patients present results outside these frameworks, clinicians should review them respectfully, explain their limitations, and switch to suitable diagnostic methods [ 213 ]. Likewise, chelating asymptomatic patients with low-level biomarkers without ongoing high-risk exposure violates proportionality, as the risks and costs surpass potential benefits [ 168 ].

Informed consent for chelation therapy must be comprehensive. Patients should be clear about the expected benefits, such as biomarker reductions and symptom relief in certain cases, as well as uncertainties, like the potential lack of improvement in functional outcomes, especially in cases of chronic low-level exposure [ 153 ]. They should also understand available alternatives, including source control, supportive care, and watchful monitoring, along with the associated risks like rash, hypersensitivity, transaminitis, cytopenias, and nephrotoxicity for some agents [ 214 ]. The consent process should also address logistical details, such as the need for ongoing lab monitoring, potential mineral supplements, and the meaning of “stopping rules [ 153 ].” For pediatric patients, obtaining assent and providing caregiver education are critical, while for pregnant patients, consent must explicitly weigh maternal benefits against fetal risks.

Justice and fairness demand that clinicians identify and address structural obstacles to prevention and treatment. For example, families living in older homes might lack the resources or landlord cooperation needed to fix lead hazards, well owners might not be able to afford arsenic filtration, and workers could face job loss if they report unsafe working conditions. Clinicians are ethically justified to advocate by writing letters supporting remediation, helping patients access public assistance programs, and documenting medical removal needs in occupational cases [ 153 ]. On a broader scale, health systems can collaborate with public health agencies to provide bundled services that lower exposure risk, offering these services at no cost to patients who cannot afford them.

Misinformation flourishes amid uncertainty [ 213 ]. To combat it, use straightforward language and actively engage with patient concerns instead of dismissing them [ 216 ]. Offer clear, practical advice such as which fish to select, how to cook rice, ways to clean window troughs safely, and the appropriate PPE for work, and explain why certain tests or supplements are not advisable [ 216 ]. Share trustworthy resources and encourage questions; the aim is to align patients and clinicians around shared priorities, safety, effectiveness, and responsible resource use.

Medico-legal responsibilities include thoroughly documenting exposure history, lab results alongside collection conditions (such as seafood avoidance in arsenic speciation), counseling given, and reasoning for or against chelation [ 149 ]. If mandatory reporting is required (like pediatric lead cases), respond promptly and keep records of notifications. In occupational scenarios, record recommendations regarding work restrictions, medical removal, and criteria for return to work; offer clear guidance to employers while safeguarding patient confidentiality [ 150 ]. When litigation might be anticipated, consider chain-of-custody protocols and collaborate with the laboratory to ensure proper containers, preservatives, and handling procedures.

Team-based safeguards assist in managing ethical and legal challenges [ 217 ]. Create multidisciplinary case reviews for complex or controversial cases, involving toxicology, nephrology, obstetrics, occupational medicine, social work, and legal advice as needed [ 218 ]. Use checklists for chelation initiation that cover indication review, baseline laboratory tests, informed consent, public health reporting, and follow-up planning [ 219 ]. Incorporate EHR decision support to identify non-validated tests and suggest evidence-based options [ 220 ]. Monitor and improve by tracking adverse events, inappropriate chelation occurrences, and patient feedback; share results openly [ 221 ].

In summary, a responsible and legally compliant approach to managing heavy metal exposure emphasizes prevention, aligns with evidence, and centers on patient needs [ 218 ]. It avoids focusing solely on numerical treatment, prioritizes controlling the exposure source, uses chelation therapy when clinically appropriate, and assists patients in overcoming social and structural barriers that often contribute to initial exposure [ 221 ].

14. Discussions: Translating Toxicology into Clinical and Public-Health Decision-Making

A key insight from combining Hg, Pb, Cd, and As data across exposure science, clinical toxicology, and public health is that biomarkers are essential but not enough for reliable decision-making [ 147 ]. These biomarkers vary based on speciation, matrix, timing, and individual factors; they distill complex and dynamic exposures into a single value that, without proper context, can be misinterpreted (see Table 16 ). Therefore, the discussion reverts to core principles: (1) understanding the patient’s exposure history and ability to modify it, (2) early recognition of organ-system effects, (3) clear criteria for escalation to treatments like chelation or hospitalization, and (4) ongoing focus on safety and equity [ 222 ].

A recurring theme is the nonlinearity between biomarker changes and clinical outcomes. For example, in pediatric cases, succimer reduces blood lead levels, but randomized trials have not shown improvements in neuropsychological endpoints among asymptomatic children with moderate elevations when source control is present [ 169 ]. The point is not that biomarkers are useless but that they should be linked with meaningful outcomes, such as development, function, and quality of life, and considered over appropriate biological timeframes [ 222 ]. Similarly, with methylmercury, the key “treatment” is dietary counseling and adherence; chelation often adds little, but serial hair or blood mercury tests can confirm reduced exposure and promote behavior changes [ 167 ]. Conversely, in cases of acute inorganic arsenic poisoning or severe lead encephalopathy, biomarkers and outcomes align during intensive treatment; here, chelation can be life-saving, and delays can be detrimental [ 223 ].

Speciation is central to many clinical decision points [ 222 ]. For instance, elevated whole-blood mercury from fish consumption requires a different approach than elevated urine mercury in a dental worker. Similarly, total urine arsenic without speciation is meaningless after a seafood meal [ 154 ]. The key takeaway is to order the correct test initially and give pre-analytic instructions, like seafood avoidance, to ensure meaningful results. When labs cannot perform speciation, clinicians should prioritize patient history, conduct repeat tests after avoidance periods, or refer to specialized labs instead of defaulting to empiric chelation [ 224 ].

Supportive and preventive management often has more impact than is typically recognized [ 225 ]. For various metals, the most effective intervention is to remove or reduce exposure, enabling clinical teams to help the greatest number of patients [ 147 ]. Since exposure controls often depend on landlord cooperation, workplace adherence, or infrastructure improvements, clinicians should build partnerships with housing authorities, occupational health services, community organizations, and legal aid [ 226 ]. These collaborations facilitate turning recommendations into tangible actions, especially when social factors limit patients’ ability to act independently [ 226 ].

The approach to chelation is more complex than simply equating a high number with treatment necessity [ 223 ]. Besides emergency situations, a careful trial of exposure control paired with close monitoring often represents the best initial step. When chelation is necessary, success depends heavily on logistics, such as collecting specimens before administering the first dose, choosing regimens suitable for the patient’s age and kidney function, replacing essential minerals, planning laboratory tests, and establishing clear stopping criteria [ 222 ]. A structured, checklist-based method helps prevent both unnecessary overuse and unsafe under-monitoring [ 227 ]. Although adverse drug events are rare with oral agents, they are more likely with parenteral routes, polypharmacy, CKD, and pregnancy, underscoring the importance of multidisciplinary oversight and explicit consent [ 228 ].

Equity runs through the entire concept of clinical effectiveness [ 225 ]. The communities most at risk, such as those with older housing, contaminated wells, and unstable jobs, face the biggest hurdles to exposure reduction and follow-up care [ 226 ]. In these environments, chelation might be used even when complete remediation is not possible, not because it is the best solution, but because it is the only manageable option [ 223 ]. An equitable strategy broadens the range of accessible interventions by incorporating programs that provide remediation, filters, safer renovations, and workplace controls alongside clinical treatments. Tracking and reporting outcomes that are sensitive to equity, such as time to source control, return to work with protections, and access to filters or abatement, helps highlight and address disparities [ 228 ].

Another common challenge is the appeal of “detox” stories in media. Patients with vague symptoms and no clear diagnosis may be convinced by marketing that hair analysis or provoked urine tests prove hidden poisoning, and that infusions will cure them. Confronting these beliefs can harm trust. A better approach is to focus on shared goals, such as feeling better and staying safe, explaining what evidence-based tests can and cannot indicate, and propose a plan starting with simple, low-risk actions like keeping an exposure diary, making dietary changes, and implementing safer household practices. If proper testing later detects a specific exposure, chelation options remain available; if not, the patient still gains from safer habits and maintains a strong therapeutic relationship.

Ultimately, the field requires tighter feedback loops linking research and practice [ 229 ]. Population-based evidence highlights risks at biomarker levels common in everyday life; clinical trials determine where drugs are effective; implementation science explores how to deliver prevention and care within limited settings [ 228 ]. When guidelines integrate all three elements and electronic health records (EHRs) encode them as defaults, everyday care becomes both more consistent and equitable. The conversation thus returns to its starting point: begin with the exposure story, select the appropriate test, implement the most impactful controls, use chelation when beneficial, and focus on measuring what truly matters.

15. Conclusions

This review presents a straightforward yet disciplined approach to managing Hg, Pb, Cd, and As exposure, aligning complex toxicology with practical medical application. First, emphasize prevention and source control, as reducing or eliminating exposure offers the greatest benefit with the least risk and cost across various settings. Second, tailor diagnostics to inform decisions by selecting tests that genuinely influence management, such as speciation when it impacts counseling or medication choices; venous confirmation for positive screenings; creatinine-corrected urine for assessing renal burden; and hair analysis only when protocols ensure accurate interpretation. Third, focus on treating patients rather than just numbers. Understand that biomarker reduction alone is not a patient-centered goal, and that functional recovery depends on factors like timing, age, organ involvement, and the effectiveness of exposure control.

Fourth, reserve chelation for patients who are most likely to benefit. Emergency cases, such as lead encephalopathy, acute inorganic arsenic poisoning, or severe inorganic mercury poisoning with renal injury—require prompt, protocolized chelation combined with ICU-level supportive care. In other situations, oral chelation (like DMSA or DMPS) may be appropriate when symptoms and biomarker levels justify the risks and logistical considerations, especially after exposure is controlled. When using chelation, safety is critical: perform baseline labs, follow weight-based dosing, monitor minerals, watch for hypersensitivity, and have clear stopping rules. Fifth, incorporate equity and ethics into care. Collaborate with public health, housing, and employers to align treatment with patients’ real-life circumstances; avoid using unvalidated tests and low-value treatments; and ensure thorough informed consent that respects patient autonomy without shifting undue risk onto those least able to handle it.

For clinicians, three practical algorithms can be derived from these principles. For lead, risk screening should be followed by measurement of venous blood lead level (BLL), implementation of exposure control, and chelation only when symptoms are present or the BLL exceeds age-specific thresholds. Remediation should be confirmed, and patients should be monitored for rebound. For mercury and arsenic, the first step is to identify the chemical species involved. In cases of dietary methylmercury (MeHg) exposure, counseling and exposure reduction are usually the primary interventions. In cases of inorganic mercury or inorganic arsenic (iAs) exposure with organ injury or markedly elevated levels, DMPS or DMSA may be considered, with BAL reserved for severe arsenic toxicity, while renal and hepatic function are monitored throughout treatment. Therapy should be discontinued once biomarker levels decline and symptoms resolve. For cadmium, renal tubular injury should be confirmed using appropriate biomarkers; chelation is generally not recommended, and management should focus on exposure reduction and control of CKD risk factors such as hypertension and hyperglycemia.

Health systems and policymakers can put these findings into practice by investing in upstream measures like replacing lead service lines, ensuring arsenic-safe wells, enforcing safer renovation practices, and implementing workplace controls (see Table 17 ). Additionally, integrating clinical pathways into EHRs with default orders and referral links can streamline care. Educational initiatives should focus on clinicians, covering topics such as speciation interpretation and pitfalls of provocation testing, and on patients, promoting clear, culturally appropriate behavior changes. Key metrics to monitor include the time taken to achieve exposure control, the proportion of appropriate chelation therapy, adverse events, patient-reported outcomes, and equity indicators like access to remediation.

In summary, current approaches to Hg, Pb, Cd, and As prioritize prevention, evidence-based practices, and patient-centered care. Chelation is viewed as a valuable but limited tool, not a universal solution. Emphasis is placed on diagnostics that inform management decisions rather than those that only satisfy curiosity. When clinicians, labs, and public health agencies coordinate using the same guidelines, patients experience dual benefits: reduced exposures and safer, prompter, and effective treatments when necessary.

16. Future Directions and Research Gaps

Future work should focus on clinically actionable advances instead of just expanding descriptive data. Important objectives include developing validated rapid speciation techniques that guide treatment, conducting prospective studies to identify significant low-level outcome thresholds, testing safer and more targeted chelators against existing standards, creating precision-toxicology algorithms that incorporate host susceptibility, and carrying out implementation research to assess equity, scalability, and cost-effectiveness in real-world healthcare environments.

Initial diagnostics for speciation are crucial. Affordable and rapid testing for mercury and arsenic, either at the point of care or with quick results from regional labs would help prevent misclassification and enable faster, appropriate interventions like dietary advice, chelation, or remediation. Research should focus on evaluating new analytical technologies, such as portable mass spectrometry and electrochemical sensors, and determine clinically validated cut-offs linked to health outcomes, not just exposure levels.

Validated clinical endpoints are necessary for low-level exposure. Although many associations at low biomarker levels are statistically significant, they tend to be small, making it difficult to translate these findings into clear clinical thresholds. Prospective cohort studies that include standardized neurocognitive, renal, cardiovascular, and reproductive endpoints along with repeated biomarker measurements and exposure diaries can help clarify dose–response relationships and guide patient-centered decision-making. Additionally, research should explore whether intensive prevention strategies, such as filters, abatement, and dietary guidance, can enhance these endpoints more cost-effectively than chelation therapy in borderline areas.

Selective, safer chelation involves prioritizing ligands that target toxic metals with greater specificity than essential ones. It includes developing prodrugs activated specifically in target tissues and creating formulations that minimize hypersensitivity and gastrointestinal intolerance. Preclinical studies should compare these new agents directly against existing treatments like DMSA, DMPS, CaNa 2 EDTA, and BAL, paying close attention to mineral balance, microbiome impacts, and rebound effects early on. In early clinical trials, it is crucial to monitor both biomarkers and functional health outcomes, with efforts to include special populations such as children, pregnant women, and individuals with CKD whenever possible.

Precision toxicology involves understanding the roles of the host and microbiome. Genetic polymorphisms such as those in AS3MT for arsenic methylation or in transporters for lead and cadmium, as well as microbiome composition, might account for individual differences in risk and treatment response. The focus of research should shift from mere associations to actionable insights: developing algorithms that combine genotype, metabolomics, diet, and environment to determine who needs chelation therapy, who would benefit most from prevention alone, and identifying the most effective agent and dosage. Clinical trials should evaluate genotype-guided chelation strategies against standard care, emphasizing patient-centered outcomes.

Implementation science and equity are crucial. Even the most effective interventions will not succeed if they are not accessible where risk is highest. Cluster-randomized or stepped-wedge trials that combine environmental services (such as inspection, remediation, and filters) with clinical care should track metrics like time to source control, biomarker changes, adverse events, and QALYs, all broken down by social risk factors. Additionally, policies and payment systems should explore financing strategies, like utility subsidies, landlord incentives, or employer mandates, that support prevention efforts while reducing long-term health costs.

Digital and decision-support tools, such as EHR-integrated pathways with default orders for essential tests, including speciation, and automatic notifications to public health, can speed up responses. Patient-facing apps can assist with fish selection, rice preparation, and filter upkeep. Research is needed to assess how well these tools are adopted, their usability, and their effects on outcomes and costs. Open-source toolkits would enable quick sharing across different resource settings.

Table 18 summarizes key future research and implementation priorities, highlighting exemplar study designs, primary endpoints, and the policy or clinical levers needed to translate evidence into practice.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

References

1. World Health Organization Ten Chemicals of Major Health Concern WHO Geneva, Switzerland 2020 Available online: https://www.who.int/news-room/photo-story/detail/10-chemicals-of-public-health-concern (accessed on 25 December 2024)

2. Agency for Toxic Substances and Disease Registry Substance Priority List ATDSR Atlanta, GA, USA 2024 Available online: https://www.atsdr.cdc.gov/ (accessed on 25 December 2025)

3. Kabata-Pendias A. Mukherjee A.B. Trace Elements from Soil to Human Springer Berlin/Heidelberg, Germany 2007 10.1007/978-3-540-32714-1

4. Hans Wedepohl K. The composition of the continental crust Geochim. Cosmochim. Acta 1995 59 1217 1232 10.1016/0016-7037(95)00038-2

5. Taylor S.R. McLennan S.M. The geochemical evolution of the continental crust Rev. Geophys. 1995 33 241 265 10.1029/95RG00262

6. Nriagu J.O. A global assessment of natural sources of atmospheric trace metals Nature 1989 338 47 49 10.1038/338047a0

7. Boldyrev M. Lead: Properties, history, and applications Wiki J. Sci. 2018 1 7 10.15347/wjs/2018.007

8. Chunhabundit R. Cadmium Exposure and Potential Health Risk from Foods in Contaminated Area, Thailand Toxicol. Res. 2016 32 65 72 10.5487/TR.2016.32.1.065 26977260 PMC4780235

9. Mann S. Droz P.-O. Vahter M. A Physiologically Based Pharmacokinetic Model for Arsenic Exposure Toxicol. Appl. Pharmacol. 1996 140 471 486 10.1006/taap.1996.0244 8887465

10. Rahman Z. Singh V.P. The relative impact of toxic heavy metals (THMs) (arsenic (As), cadmium (Cd), chromium (Cr)(VI), mercury (Hg), and lead (Pb)) on the total environment: An overview Environ. Monit. Assess. 2019 191 419 10.1007/s10661-019-7528-7 31177337

11. Balali-Mood M. Naseri K. Tahergorabi Z. Khazdair M.R. Sadeghi M. Toxic Mechanisms of Five Heavy Metals: Mercury, Lead, Chromium, Cadmium, and Arsenic Front. Pharmacol. 2021 12 643972 10.3389/fphar.2021.643972 33927623 PMC8078867

12. Meyer L. Guyot S. Chalot M. Capelli N. The potential of microorganisms as biomonitoring and bioremediation tools for mercury-contaminated soils Ecotoxicol. Environ. Saf. 2023 262 115185 10.1016/j.ecoenv.2023.115185 37385017

13. Adriano D.C. Trace Elements in Terrestrial Environments Springer New York, NY, USA 2001 10.1007/978-0-387-21510-5

14. Alloway B.J. Heavy Metals in Soils: Trace Metals and Metalloids in Soils and Their Bioavailability Environmental Pollution Springer Dordrecht, The Netherlands 2013 Volume 22 10.1007/978-94-007-4470-7

15. Pirrone N. Cinnirella S. Feng X. Finkelman R.B. Friedli H.R. Leaner J. Mason R. Mukherjee A.B. Stracher G.B. Streets D.G. Global mercury emissions to the atmosphere from anthropogenic and natural sources Atmos. Chem. Phys. 2010 10 5951 5964 10.5194/acp-10-5951-2010

16. Crea F. Foti C. Milea D. Sammartano S. Speciation of Cadmium in the Environment Cadmium: From Toxicity to Essentiality Sigel A. Sigel H. Sigel R.K. Metal Ions in Life Sciences Springer Dordrecht, The Netherlands 2013 Volume 11 63 83 10.1007/978-94-007-5179-8_3 23430770

17. Shankar S. Shanker U. Shikha Arsenic contamination of groundwater: A review of sources, prevalence, health risks, and strategies for mitigation Sci. World J. 2014 2014 304524 10.1155/2014/304524 PMC4211162 25374935

18. Pacyna E.G. Pacyna J.M. Steenhuisen F. Wilson S. Global anthropogenic mercury emission inventory for 2000 Atmos. Environ. 2006 40 4048 4063 10.1016/j.atmosenv.2006.03.041

19. Streets D.G. Zhang Q. Wu Y. Projections of Global Mercury Emissions in 2050 Environ. Sci. Technol. 2009 43 2983 2988 10.1021/es802474j 19475981

20. Selin N.E. Global Biogeochemical Cycling of Mercury: A Review Annu. Rev. Environ. Resour. 2009 34 43 63 10.1146/annurev.environ.051308.084314

21. Lindberg S. Bullock R. Ebinghaus R. Engstrom D. Feng X. Fitzgerald W. Pirrone N. Prestbo E. Seigneur C. A Synthesis of Progress and Uncertainties in Attributing the Sources of Mercury in Deposition AMBIO J. Hum. Environ. 2007 36 19 33 10.1579/0044-7447(2007)36[19:ASOPAU]2.0.CO;2 17408188

22. Schroeder W.H. Munthe J. Atmospheric mercury—An overview Atmos. Environ. 1998 32 809 822 10.1016/S1352-2310(97)00293-8

23. Feng X. Bigham G.N. Mercury biogeochemical cycling in mercury contaminated environments Appl. Geochem. 2011 26 153 10.1016/j.apgeochem.2010.11.012

24. Ariya P.A. Amyot M. Dastoor A. Deeds D. Feinberg A. Kos G. Poulain A. Ryjkov A. Semeniuk K. Subir M. Mercury Physicochemical and Biogeochemical Transformation in the Atmosphere and at Atmospheric Interfaces: A Review and Future Directions Chem. Rev. 2015 115 3760 3802 10.1021/cr500667e 25928690

25. Zhang Y. Jaeglé L. Thompson L. Streets D.G. Six centuries of changing oceanic mercury Glob. Biogeochem. Cycles 2014 28 1251 1261 10.1002/2014GB004939

26. Mahaffey K.R. Environmental lead toxicity: Nutrition as a component of intervention Environ. Health Perspect. 1990 89 75 78 10.1289/ehp.908975 2088758 PMC1567783

27. Needleman H. Lead Poisoning Annu. Rev. Med. 2004 55 209 222 10.1146/annurev.med.55.091902.103653 14746518

28. Watanabe T. Kasahara M. Nakatsuka H. Ikeda M. Cadmium and lead contents of cigarettes produced in various areas of the world1 Sci. Total Environ. 1987 66 29 37 10.1016/0048-9697(87)90074-X 3685955

29. Degryse F. Smolders E. Parker D.R. Partitioning of metals (Cd, Co, Cu, Ni, Pb, Zn) in soils: Concepts, methodologies, prediction and applications—A review Eur. J. Soil Sci. 2009 60 590 612 10.1111/j.1365-2389.2009.01142.x

30. Sonmez M.S. Kumar R.V. Leaching of waste battery paste components. Part 1: Lead citrate synthesis from PbO and PbO 2 Hydrometallurgy 2009 95 53 60 10.1016/j.hydromet.2008.04.012

31. Lanphear B.P. Cognitive Deficits Associated with Blood Lead Concentrations <10 microg/dL in US Children and Adolescents Public Health Rep. 2000 115 521 529 10.1093/phr/115.6.521 11354334 PMC1308622

32. Mielke H.W. Reagan P.L. Soil is an important pathway of human lead exposure Environ. Health Perspect. 1998 106 217 229 10.1289/ehp.98106s1217 9539015 PMC1533263

33. Jonsson A. Lindström M. Bergbäck B. Phasing out cadmium and lead—Emissions and sediment loads in an urban area Sci. Total Environ. 2002 292 91 100 10.1016/S0048-9697(02)00029-3 12108449

34. Nriagu J.O. Pacyna J.M. Quantitative assessment of worldwide contamination of air, water and soils by trace metals Nature 1988 333 134 139 10.1038/333134a0 3285219

35. Chen A. Dietrich K.N. Huo X. Ho S. Developmental Neurotoxicants in E-Waste: An Emerging Health Concern Environ. Health Perspect. 2011 119 431 438 10.1289/ehp.1002452 21081302 PMC3080922

36. Engström K.S. Vahter M. Fletcher T. Leonardi G. Goessler W. Gurzau E. Koppova K. Rudnai P. Kumar R. Broberg K. Genetic variation in arsenic (+3 oxidation state) methyltransferase ( AS3MT ), arsenic metabolism and risk of basal cell carcinoma in a E uropean population Environ. Mol. Mutagen. 2015 56 60 69 10.1002/em.21896 25156000 PMC4322484

37. Nordberg G. Sandstrom B. Becking G. Goyer R.A. Essentiality and toxicity of trace elements: Principles and methods for assessment of risk from human exposure to essential trace elements J. Trace Elem. Exp. Med. 2000 13 141 153 10.1002/(SICI)1520-670X(2000)13:1<141::AID-JTRA15>3.0.CO;2-A

38. Peng Q. Greenfield B.K. Dang F. Zhong H. Human exposure to methylmercury from crayfish ( Procambarus clarkii ) in China Environ. Geochem. Health 2016 38 169 181 10.1007/s10653-015-9701-4 25850898

39. Homme K.G. Kern J.K. Haley B.E. Geier D.A. King P.G. Sykes L.K. Geier M.R. New science challenges old notion that mercury dental amalgam is safe BioMetals 2014 27 19 24 10.1007/s10534-013-9700-9 24420334 PMC3905169

40. Milioni A.L.V. Nagy B.V. Moura A.L.A. Zachi E.C. Barboni M.T.S. Ventura D.F. Neurotoxic impact of mercury on the central nervous system evaluated by neuropsychological tests and on the autonomic nervous system evaluated by dynamic pupillometry NeuroToxicology 2017 59 263 269 10.1016/j.neuro.2016.04.010 27090823

41. Roman H.A. Walsh T.L. Coull B.A. Dewailly É. Guallar E. Hattis D. Mariën K. Schwartz J. Stern A.H. Virtanen J.K. Evaluation of the Cardiovascular Effects of Methylmercury Exposures: Current Evidence Supports Development of a Dose–Response Function for Regulatory Benefits Analysis Environ. Health Perspect. 2011 119 607 614 10.1289/ehp.1003012 21220222 PMC3094409

42. Bose-O’Reilly S. McCarty K.M. Steckling N. Lettmeier B. Mercury Exposure and Children’s Health Curr. Probl. Pediatr. Adolesc. Health Care 2010 40 186 215 10.1016/j.cppeds.2010.07.002 20816346 PMC3096006

43. Levin R. Brown M.J. Kashtock M.E. Jacobs D.E. Whelan E.A. Rodman J. Schock M.R. Padilla A. Sinks T. Lead Exposures in U.S. Children, 2008: Implications for Prevention Environ. Health Perspect. 2008 116 1285 1293 10.1289/ehp.11241 18941567 PMC2569084

44. PREDIMED Study Investigators Downer M.K. Martínez-González M.A. Gea A. Stampfer M. Warnberg J. Ruiz-Canela M. Salas-Salvadó J. Corella D. Ros E. Mercury exposure and risk of cardiovascular disease: A nested case-control study in the PREDIMED (PREvention with MEDiterranean Diet) study BMC Cardiovasc. Disord. 2017 17 9 10.1186/s12872-016-0435-8 28056794 PMC5216562

45. Bellinger D.C. Very low lead exposures and children’s neurodevelopment Curr. Opin. Pediatr. 2008 20 172 177 10.1097/MOP.0b013e3282f4f97b 18332714

46. Navas-Acien A. Guallar E. Silbergeld E.K. Rothenberg S.J. Lead Exposure and Cardiovascular Disease—A Systematic Review Environ. Health Perspect. 2007 115 472 482 10.1289/ehp.9785 17431501 PMC1849948

47. Person R.J. Tokar E.J. Xu Y. Orihuela R. Ngalame N.N.O. Waalkes M.P. Chronic cadmium exposure in vitro induces cancer cell characteristics in human lung cells Toxicol. Appl. Pharmacol. 2013 273 281 288 10.1016/j.taap.2013.06.013 23811327 PMC3863781

48. Järup L. Hazards of heavy metal contamination Br. Med. Bull. 2003 68 167 182 10.1093/bmb/ldg032 14757716

49. Marano K.M. Naufal Z.S. Kathman S.J. Bodnar J.A. Borgerding M.F. Garner C.D. Wilson C.L. Cadmium exposure and tobacco consumption: Biomarkers and risk assessment Regul. Toxicol. Pharmacol. 2012 64 243 252 10.1016/j.yrtph.2012.07.008 22902766

50. Agency for Toxic Substances and Disease Registry. U.S. Department of Health and Human Services Available online: https://www.atsdr.cdc.gov/toxprofiles/tp5.pdf (accessed on 25 December 2025)

51. Moon S. Lee J. Yu J.M. Choi H. Choi S. Park J. Choi K. Kim E. Kim H. Kim M.J. Association between environmental cadmium exposure and increased mortality in the U.S. National Health and Nutrition Examination Survey (1999–2018) J. Expo. Sci. Environ. Epidemiol. 2023 33 874 882 10.1038/s41370-023-00556-8 37161056

52. Satarug S. Moore M.R. Adverse Health Effects of Chronic Exposure to Low-Level Cadmium in Foodstuffs and Cigarette Smoke Environ. Health Perspect. 2004 112 1099 1103 10.1289/ehp.6751 15238284 PMC1247384

53. Hernandez M. Schuhmacher M. Fernandez J.D. Domingo J.L. Llobet J.M. Urinary cadmium levels during pregnancy and postpartum: A longitudinal study Biol. Trace Elem. Res. 1996 53 205 212 10.1007/BF02784556 8862749

54. Nishijo M. Nakagawa H. Honda R. Tanebe K. Saito S. Teranishi H. Tawara K. Effects of maternal exposure to cadmium on pregnancy outcome and breast milk Occup. Environ. Med. 2002 59 394 397 10.1136/oem.59.6.394 12040115 PMC1740300

55. Zhao L. Ru Y. Liu M. Tang J. Zheng J. Wu B. Gu Y. Shi H. Reproductive effects of cadmium on sperm function and early embryonic development in vitro PLoS ONE 2017 12 e0186727 10.1371/journal.pone.0186727 29095856 PMC5667747

56. Ziegler E.E. Edwards B.B. Jensen R.L. Mahaffey K.R. Fomon S.J. Absorption and Retention of Lead by Infants Pediatr. Res. 1978 12 29 34 10.1203/00006450-197801000-00008 643372

57. Bradman A. Eskenazi B. Sutton P. Athanasoulis M. Goldman L.R. Iron deficiency associated with higher blood lead in children living in contaminated environments Environ. Health Perspect. 2001 109 1079 1084 10.1289/ehp.011091079 11675273 PMC1242086

58. Gulson B.L. Mizon K.J. Korsch M.J. Palmer J.M. Donnelly J.B. Mobilization of lead from human bone tissue during pregnancy and lactation—A summary of long-term research Sci. Total Environ. 2003 303 79 104 10.1016/S0048-9697(02)00355-8 12568766

59. Canfield R.L. Kreher D.A. Cornwell C. Henderson C.R. Low-Level Lead Exposure, Executive Functioning, and Learning in Early Childhood Child Neuropsychol. 2003 9 35 53 10.1076/chin.9.1.35.14496 12815521

60. Berglund M. Lind B. Björnberg K.A. Palm B. Einarsson O. Vahter M. Inter-individual variations of human mercury exposure biomarkers: A cross-sectional assessment Environ. Health 2005 4 20 10.1186/1476-069X-4-20 16202128 PMC1262739

61. Satarug S. Ruangyuttikarn W. Nishijo M. Ruiz P. Urinary Cadmium Threshold to Prevent Kidney Disease Development Toxics 2018 6 26 10.3390/toxics6020026 29723981 PMC6027056

62. Jones M.R. Tellez-Plaza M. Vaidya D. Grau M. Francesconi K.A. Goessler W. Guallar E. Post W.S. Kaufman J.D. Navas-Acien A. Estimation of Inorganic Arsenic Exposure in Populations with Frequent Seafood Intake: Evidence from MESA and NHANES Am. J. Epidemiol. 2016 184 590 602 10.1093/aje/kww097 27702745 PMC5065621

63. Packer L. Witt E.H. Tritschler H.J. Alpha-lipoic acid as a biological antioxidant Free Radic. Biol. Med. 1995 19 227 250 10.1016/0891-5849(95)00017-R 7649494

64. Ballatori N. Lieberman M.W. N-Acetylcysteine as an Antidote in Methylmercury Poisoning Environ. Health Perspect. 1998 106 267 271 10.1289/ehp.98106267 9520359 PMC1533084

65. Aaseth J. Skaug M.A. Cao Y. Andersen O. Chelation in metal intoxication—Principles and paradigms J. Trace Elem. Med. Biol. 2015 31 260 266 10.1016/j.jtemb.2014.10.001 25457281

66. Dapul H. Laraque D. Lead poisoning in children Adv. Pediatr. 2014 61 313 333 10.1016/j.yapd.2014.04.004 25037135

67. Meister A. Anderson M.E. GLUTATHIONE Annu. Rev. Biochem. 1983 52 711 760 10.1146/annurev.bi.52.070183.003431 6137189

68. Blaurock-Busch E. Comparison of Chelating Agents DMPS, DMSA and EDTA for the Diagnosis and Treatment of Chronic Metal Exposure Br. J. Med. Med. Res. 2014 4 1821 1835 10.9734/BJMMR/2014/6875

69. Jacob S. Henriksen E.J. Schiemann A.L. Simon I. Clancy D.E. Tritschler H.J. Jung W.I. Augustin H.J. Dietze G.J. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid Arzneimittelforschung 1995 45 872 874 7575750

70. Kosnett M.J. Unithiol (DMPS) Critical Care Toxicology Brent J. Burkhart K. Dargan P. Hatten B. Megarbane B. Palmer R. Springer International Publishing Cham, Switzerland 2016 1 4 10.1007/978-3-319-20790-2_21-1

71. Gerhardsson L. Aaseth J. Guidance for Clinical Treatment of Metal Poisonings—Use and Misuse of Chelating Agents Chelation Therapy in the Treatment of Metal Intoxication Elsevier Amsterdam, The Netherlands 2016 313 341 10.1016/B978-0-12-803072-1.00007-9

72. California Poison Control System (CPCS) Antidote Chart Available online: https://calpoison.org/antidotes (accessed on 15 October 2024)

73. Illinois Poison Center IPC Poison Antidote Stocking Chart Available online: https://www.illinoispoisoncenter.org/getmedia/f7c14fba-03bf-44b8-b589-32f6f552f6c7/ipc-antidote-stocking-list-2022_final-edit.pdf (accessed on 10 September 2024)

74. Bjørklund G. Aaseth J. Crisponi G. Rahman M.M. Chirumbolo S. Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology J. Inorg. Biochem. 2019 195 111 119 10.1016/j.jinorgbio.2019.03.019 30939378

75. Vafaee F. Derakhshani M. Ghasemzadeh Rahbardar M. Hosseinzadeh H. Alpha-lipoic acid, as an effective agent against toxic elements: A review Naunyn-Schmiedeberg’s Arch. Pharmacol. 2025 398 3345 3372 10.1007/s00210-024-03576-9 39556148

76. Campbell J.R. The Therapeutic Use of 2,3-Dimercaptopropane-1-Sulfonate in Two Cases of Inorganic Mercury Poisoning JAMA J. Am. Med. Assoc. 1986 256 3127 10.1001/jama.1986.03380220093029 3783847

77. Keattanong P. Wasukan N. Kuno M. Srisung S. Synthesis, structural characterization, computational studies and stability evaluations of metal ions and ZnONPs complexes with dimercaptosuccinic acid Heliyon 2021 7 e05962 10.1016/j.heliyon.2021.e05962 33553730 PMC7851782

78. Fang X. Hua F. Fernando Q. Comparison of rac - and meso -2,3-Dimercaptosuccinic Acids for Chelation of Mercury and Cadmium Using Chemical Speciation Models Chem. Res. Toxicol. 1996 9 284 290 10.1021/tx950096o 8924605

79. Bjørklund G. Crisponi G. Nurchi V.M. Cappai R. Buha Djordjevic A. Aaseth J. A Review on Coordination Properties of Thiol-Containing Chelating Agents Towards Mercury, Cadmium, and Lead Molecules 2019 24 3247 10.3390/molecules24183247 31489907 PMC6767255

80. Andersen O. Aaseth J. A review of pitfalls and progress in chelation treatment of metal poisonings J. Trace Elem. Med. Biol. 2016 38 74 80 10.1016/j.jtemb.2016.03.013 27150911

81. Wu G. Lupton J.R. Turner N.D. Fang Y.-Z. Yang S. Glutathione Metabolism and Its Implications for Health J. Nutr. 2004 134 489 492 10.1093/jn/134.3.489 14988435

82. Lu S.C. Regulation of glutathione synthesis Mol. Asp. Med. 2009 30 42 59 10.1016/j.mam.2008.05.005 PMC2704241 18601945

83. Chisolm J.J. Safety and Efficacy of Meso-2,3-Dimercaptosuccinic Acid (DMSA) in Children with Elevated Blood Lead Concentrations J. Toxicol. Clin. Toxicol. 2000 38 365 375 10.1081/CLT-100100945 10930052

84. Behari J.R. Srivastava S. Gupta S. Srivastava R.C. Effect of liposome encapsulated meso-2,3-dimercaptosuccinic acid (DMSA) on biochemical and trace metal alterations in cadmium exposed rats Bull. Environ. Contam. Toxicol. 1991 47 827 833 10.1007/BF01689511 1686193

85. Vasken Aposhian H. Maiorino R.M. Rivera M. Bruce D.C. Dart R.C. Hurlbut K.M. Levine D.J. Zheng W. Fernando Q. Carter D. Human Studies with the Chelating Agents, DMPS and DMSA J. Toxicol. Clin. Toxicol. 1992 30 505 528 10.3109/15563659209017938 1331491

86. Bradberry S. Vale A. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning Clin. Toxicol. 2009 47 841 858 10.3109/15563650903321064 19852620

87. Spiller H.A. Hays H.L. Casavant M.J. Rethinking treatment of mercury poisoning: The roles of selenium, acetylcysteine, and thiol chelators in the treatment of mercury poisoning: A narrative review Toxicol. Commun. 2021 5 19 59 10.1080/24734306.2020.1870077

88. Pfaff A.R. Beltz J. King E. Ercal N. Medicinal Thiols: Current Status and New Perspectives Mini-Rev. Med. Chem. 2020 20 513 529 10.2174/1389557519666191119144100 31746294 PMC7286615

89. Svanedal I. Boija S. Almesåker A. Persson G. Andersson F. Hedenström E. Bylund D. Norgren M. Edlund H. Metal Ion Coordination, Conditional Stability Constants, and Solution Behavior of Chelating Surfactant Metal Complexes Langmuir 2014 30 4605 4612 10.1021/la5002336 24702119

90. Reedijk J. Comprehensive Inorganic Chemistry II: From Elements to Applications 2nd ed. Elsevier Amsterdam, The Netherlands 2013

91. Farina M. Aschner M. Rocha J.B.T. Oxidative stress in MeHg-induced neurotoxicity Toxicol. Appl. Pharmacol. 2011 256 405 417 10.1016/j.taap.2011.05.001 21601588 PMC3166649

92. Kitchin K.T. Recent Advances in Arsenic Carcinogenesis: Modes of Action, Animal Model Systems, and Methylated Arsenic Metabolites Toxicol. Appl. Pharmacol. 2001 172 249 261 10.1006/taap.2001.9157 11312654

93. Haas K.L. Franz K.J. Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology Chem. Rev. 2009 109 4921 4960 10.1021/cr900134a 19715312 PMC2761982

94. Andersen O. Aaseth J. Molecular mechanisms of in vivo metal chelation: Implications for clinical treatment of metal intoxications Environ. Health Perspect. 2002 110 887 890 10.1289/ehp.02110s5887 12426153 PMC1241267

95. Aaseth J. Recent Advance in the Therapy of Metal Poisonings with Chelating Agents Hum. Toxicol. 1983 2 257 272 10.1177/096032718300200214 6345341

96. Pearson R.G. Hard and Soft Acids and Bases J. Am. Chem. Soc. 1963 85 3533 3539 10.1021/ja00905a001

97. Lewis G.N. Acids and bases J. Frankl. Inst. 1938 226 293 313 10.1016/S0016-0032(38)91691-6

98. Nordberg G.F. Fowler B.A. Nordberg M. Handbook on the Toxicology of Metals Elsevier Amsterdam, The Netherlands 2015 10.1016/C2011-0-07884-5

99. Clarkson T.W. Magos L. The Toxicology of Mercury and Its Chemical Compounds Crit. Rev. Toxicol. 2006 36 609 662 10.1080/10408440600845619 16973445

100. Aschner M. Aschner J.L. Kimelberg H.K. Methylmercury Neurotoxicity and Its Uptake Across the Blood—Brain Barrier The Vulnerable Brain and Environmental Risks Isaacson R.L. Jensen K.F. Springer Boston, MA, USA 1992 3 17 10.1007/978-1-4615-3330-6_1

101. Mahaffey K.R. Nutrition and lead: Strategies for public health Environ. Health Perspect. 1995 103 191 196 10.1289/ehp.95103s6191 8549473 PMC1518938

102. Silbergeld E.K. Schwartz J. Mahaffey K. Lead and osteoporosis: Mobilization of lead from bone in postmenopausal women Environ. Res. 1988 47 79 94 10.1016/S0013-9351(88)80023-9 3168967

103. Nordberg G.F. Historical perspectives on cadmium toxicology Toxicol. Appl. Pharmacol. 2009 238 192 200 10.1016/j.taap.2009.03.015 19341754

104. Vahter M. Mechanisms of arsenic biotransformation Toxicology 2002 181–182 211 217 10.1016/S0300-483X(02)00285-8 12505313

105. Thomas D.J. Arsenic methylation—Lessons from three decades of research Toxicology 2021 457 152800 10.1016/j.tox.2021.152800 33901604 PMC10048126

106. Nuran Ercal B.S.P. Hande Gurer-Orhan B.S.P. Nukhet Aykin-Burns B.S.P. Toxic Metals and Oxidative Stress Part I: Mechanisms Involved in Me-tal induced Oxidative Damage Curr. Top. Med. Chem. 2001 1 529 539 10.2174/1568026013394831 11895129

107. Patrick L. Lead toxicity, a review of the literature. Part 1: Exposure, evaluation, and treatment Altern. Med. Rev. J. Clin. Ther. 2006 11 2 22 16597190

108. Järup L. Åkesson A. Current status of cadmium as an environmental health problem Toxicol. Appl. Pharmacol. 2009 238 201 208 10.1016/j.taap.2009.04.020 19409405

109. Grandjean P. Herz K.T. Trace elements as paradigms of developmental neurotoxicants: Lead, methylmercury and arsenic J. Trace Elem. Med. Biol. 2015 31 130 134 10.1016/j.jtemb.2014.07.023 25175507 PMC4321972

110. Balali-Mood M. Eizadi-Mood N. Hassanian-Moghaddam H. Etemad L. Moshiri M. Vahabzadeh M. Sadeghi M. Recent advances in the clinical management of intoxication by five heavy metals: Mercury, lead, chromium, cadmium and arsenic Heliyon 2025 11 e42696 10.1016/j.heliyon.2025.e42696 40040983 PMC11876891

111. Satoh H. Occupational and Environmental Toxicology of Mercury and Its Compounds Ind. Health 2000 38 153 164 10.2486/indhealth.38.153 10812838

112. Vejrup K. Schjølberg S. Knutsen H.K. Kvalem H.E. Brantsæter A.L. Meltzer H.M. Alexander J. Magnus P. Haugen M. Prenatal methylmercury exposure and language delay at three years of age in the Norwegian Mother and Child Cohort Study Environ. Int. 2016 92–93 63 69 10.1016/j.envint.2016.03.029 27058928

113. Hsu L.-I. Chen G.-S. Lee C.-H. Yang T.-Y. Chen Y.-H. Wang Y.-H. Hsueh Y.-M. Chiou H.-Y. Wu M.-M. Chen C.-J. Use of Arsenic-Induced Palmoplantar Hyperkeratosis and Skin Cancers to Predict Risk of Subsequent Internal Malignancy Am. J. Epidemiol. 2013 177 202 212 10.1093/aje/kws369 23299695

114. Åkesson A. Barregard L. Bergdahl I.A. Nordberg G.F. Nordberg M. Skerfving S. Non-renal effects and the risk assessment of environmental cadmium exposure Environ. Health Perspect. 2014 122 431 438 10.1289/ehp.1307110 24569905 PMC4014752

115. Isbister G.K. Dawson A.H. Whyte I.M. Arsenic trioxide poisoning: A description of two acute overdoses Hum. Exp. Toxicol. 2004 23 359 364 10.1191/0960327104ht459cr 15311855

116. Besunder J.B. Super D.M. Anderson R.L. Comparison of dimercaptosuccinic acid and calcium disodium ethylenediaminetetraacetic acid versus dimercaptopropanol and ethylenediaminetetraacetic acid in children with lead poisoning J. Pediatr. 1997 130 966 971 10.1016/S0022-3476(97)70285-3 9202621

117. Lim H.E. Shim J.J. Lee S.Y. Lee S.H. Kang S.Y. Jo J.Y. In K.H. Kim H.G. Yoo S.H. Kang K.H. Mercury inhalation poisoning and acute lung injury Korean J. Intern. Med. 1998 13 127 130 10.3904/kjim.1998.13.2.127 9735669 PMC4531943

118. Francès P. Kluger N. Bluish Pigmentation of the Gingiva in a Homeless Patient: A Quiz Acta Derm. Venereol. 2012 92 109 112 10.2340/00015555-1201 21952674

119. Bernhoft R.A. Mercury Toxicity and Treatment: A Review of the Literature J. Environ. Public Health 2012 2012 460508 10.1155/2012/460508 22235210 PMC3253456

120. Park J.-D. Zheng W. Human Exposure and Health Effects of Inorganic and Elemental Mercury J. Prev. Med. Pub. Health 2012 45 344 352 10.3961/jpmph.2012.45.6.344 23230464 PMC3514464

121. Collin M.S. Venkatraman S.K. Vijayakumar N. Kanimozhi V. Arbaaz S.M. Stacey R.G.S. Anusha J. Choudhary R. Lvov V. Tovar G.I. Bioaccumulation of lead (Pb) and its effects on human: A review J. Hazard. Mater. Adv. 2022 7 100094 10.1016/j.hazadv.2022.100094

122. Helmich F. Lock G. Burton’s Line from Chronic Lead Intoxication N. Engl. J. Med. 2018 379 10.1056/NEJMicm1801693 30403939

123. Rafati-Rahimzadeh M. Rafati-Rahimzadeh M. Kazemi S. Moghadamnia A. Cadmium toxicity and treatment: An update Casp. J. Intern. Med. 2017 8 135 145 10.22088/cjim.8.3.135 PMC5596182 28932363

124. Tang G.T. Elakis J. Scardamaglia L. Cutaneous Manifestations and Treatment of Arsenic Toxicity: A Systematic Review Skin Health Dis. 2023 3 ski2.231 10.1002/ski2.231 PMC10395639 37538334

125. Hung D.-Z. Yang K.-W. Wu C.-C. Hung Y.-H. Lead poisoning due to incense burning: An outbreak in a family Clin. Toxicol. 2021 59 756 759 10.1080/15563650.2020.1853146 33263439

126. Hosseini M.-S. Salimi A. Phillips S. Zamani N. Hassanian-Moghaddam H. Adult Lead Poisoning Caused by Contaminated Opium: A Two-Year Longitudinal Follow-Up Study Ann. Glob. Health 2021 87 89 10.5334/aogh.3420 34567981 PMC8428290

127. Chiu C. Fisk C.A. Rice B.T. Garcia E.C.M. Arsenic Toxicity From the Ingestion of Terracotta Pottery J. Emerg. Med. 2022 63 363 366 10.1016/j.jemermed.2022.06.004 36229316

128. Waack A. Ranabothu M. Vattipally V. Mercury poisoning from artisanal gold mining equipment Radiol. Case Rep. 2023 18 607 609 10.1016/j.radcr.2022.10.099 36465164 PMC9713274

129. Majdanik S. Potocka-Banaś B. Glowinski S. Luzny S. Suicidal intoxication with mercury chloride Forensic Toxicol. 2023 41 304 308 10.1007/s11419-022-00653-7 36564610 PMC10310567

130. Kamal I.J. Cerbini T. Clouser A. Hernandez A. Calello D.P. Lead encephalopathy presenting as status epilepticus: A case report BMC Pediatr. 2024 24 687 10.1186/s12887-024-04871-3 39472845 PMC11520840

131. Sasaki T. Horiguchi H. Matsukawa T. Kobayashi M. Omori Y. Oguma E. Komatsuda A. A suspected case of “itai-itai disease” in a cadmium-polluted area in Akita prefecture, Japan Environ. Health Prev. Med. 2024 29 40 10.1265/ehpm.24-00063 39111871 PMC11310559

132. England J.D. Gronseth G.S. Franklin G. Carter G.T. Kinsella L.J. Cohen J.A. Asbury A.K. Szigeti K. Lupski J.R. Latov N. Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review): Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation Neurology 2009 72 185 192 10.1212/01.wnl.0000336370.51010.a1 19056666

133. Chen T.K. Knicely D.H. Grams M.E. Chronic Kidney Disease Diagnosis and Management: A Review JAMA 2019 322 1294 10.1001/jama.2019.14745 31573641 PMC7015670

134. Tefferi A. Anemia in Adults: A Contemporary Approach to Diagnosis Mayo Clin. Proc. 2003 78 1274 1280 10.4065/78.10.1274 14531486

135. Ye B.-J. Kim B.-G. Jeon M.-J. Kim S.-Y. Kim H.-C. Jang T.-W. Chae H.-J. Choi W.-J. Ha M.-N. Hong Y.-S. Evaluation of mercury exposure level, clinical diagnosis and treatment for mercury intoxication Ann. Occup. Environ. Med. 2016 28 5 10.1186/s40557-015-0086-8 26807265 PMC4724159

136. Kosnett M.J. Wedeen R.P. Rothenberg S.J. Hipkins K.L. Materna B.L. Schwartz B.S. Hu H. Woolf A. Recommendations for Medical Management of Adult Lead Exposure Environ. Health Perspect. 2007 115 463 471 10.1289/ehp.9784 17431500 PMC1849937

137. Dueñas-Laita A. Pérez-Miranda M. González-López M.A. Martín-Escudero J.C. Ruiz-Mambrilla M. Blanco-Varela J. Acute arsenic poisoning The Lancet 2005 365 1982 10.1016/S0140-6736(05)66670-6 15936431

138. Middleton D.R.S. Watts M.J. Lark R.M. Milne C.J. Polya D.A. Assessing urinary flow rate, creatinine, osmolality and other hydration adjustment methods for urinary biomonitoring using NHANES arsenic, iodine, lead and cadmium data Environ. Health Glob. Access Sci. Source 2016 15 68 10.1186/s12940-016-0152-x PMC4902931 27286873

139. Wang A. Rezania Z. Haugen K.M.B. Baertlein L. Yendell S.J. Screening for Elevated Blood Lead Levels: False-Positive Rates of Tests on Capillary Samples, Minnesota, 2011–2017 J. Public Health Manag. Pract. 2019 25 S44 S50 10.1097/PHH.0000000000000879 30507769

140. Esteban-López M. Arrebola J.P. Juliá M. Pärt P. Soto E. Cañas A. Pedraza-Díaz S. González-Rubio J. Castaño A. Selecting the best non-invasive matrix to measure mercury exposure in human biomonitoring surveys Environ. Res. 2022 204 112394 10.1016/j.envres.2021.112394 34801545

141. Trzcinka-Ochocka M. Jakubowski M. Razniewska G. Halatek T. Gazewski A. The effects of environmental cadmium exposure on kidney function: The possible influence of age Environ. Res. 2004 95 143 150 10.1016/j.envres.2003.10.003 15147919

142. Kim H.-C. Jang T.-W. Chae H.-J. Choi W.-J. Ha M.-N. Ye B.-J. Kim B.-G. Jeon M.-J. Kim S.-Y. Hong Y.-S. Evaluation and management of lead exposure Ann. Occup. Environ. Med. 2015 27 30 10.1186/s40557-015-0085-9 26677413 PMC4681084

143. Ruggieri F. Majorani C. Domanico F. Alimonti A. Mercury in Children: Current State on Exposure through Human Biomonitoring Studies Int. J. Environ. Res. Public Health 2017 14 519 10.3390/ijerph14050519 28498344 PMC5451970

144. Hsueh Y.-M. Hsu M.-K. Chiou H.-Y. Yang M.-H. Huang C.-C. Chen C.-J. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake Toxicol. Lett. 2002 133 83 91 10.1016/S0378-4274(02)00087-5 12076513

145. Jansen R.J. Argos M. Tong L. Li J. Rakibuz-Zaman M. Islam M.T. Slavkovich V. Ahmed A. Navas-Acien A. Parvez F. Determinants and Consequences of Arsenic Metabolism Efficiency among 4,794 Individuals: Demographics, Lifestyle, Genetics, and Toxicity Cancer Epidemiol. Biomark. Prev. 2016 25 381 390 10.1158/1055-9965.EPI-15-0718 PMC4767610 26677206

146. Hu H. Milder F.L. Burger D.E. The use of K X-ray fluorescence for measuring lead burden in epidemiological studies: High and low lead burdens and measurement uncertainty Environ. Health Perspect. 1991 94 107 110 10.1289/ehp.94-1567946 1954919 PMC1567946

147. Gil F. Hernández A.F. Toxicological importance of human biomonitoring of metallic and metalloid elements in different biological samples Food Chem. Toxicol. 2015 80 287 297 10.1016/j.fct.2015.03.025 25837421

148. American College of Medical Toxicology American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing J. Med. Toxicol. 2010 6 74 75 10.1007/s13181-010-0039-0 20354920 PMC3550446

149. Keil D.E. Berger-Ritchie J. McMillin G.A. Testing for Toxic Elements: A Focus on Arsenic, Cadmium, Lead, and Mercury Lab. Med. 2011 42 735 742 10.1309/LMYKGU05BEPE7IAW

150. Dinis-Oliveira R.J. Vieira D.N. Magalhães T. Guidelines for Collection of Biological Samples for Clinical and Forensic Toxicological Analysis Forensic Sci. Res. 2016 1 42 51 10.1080/20961790.2016.1271098 30483610 PMC6197137

151. Wang R.Y. Caldwell K.L. Jones R.L. Analytical Considerations in the Clinical Laboratory Assessment of Metals J. Med. Toxicol. 2014 10 232 239 10.1007/s13181-014-0381-8 24515525 PMC4057545

152. Lam J.H. Pickles K. Stanaway F.F. Bell K.J.L. Why clinicians overtest: Development of a thematic framework BMC Health Serv. Res. 2020 20 1011 10.1186/s12913-020-05844-9 33148242 PMC7643462

153. Council on Environmental Health Lanphear B.P. Lowry J.A. Ahdoot S. Baum C.R. Bernstein A.S. Bole A. Brumberg H.L. Campbell C.C. Lanphear B.P. Prevention of Childhood Lead Toxicity Pediatrics 2016 138 e20161493 Erratum in Pediatrics 2017 , 140 , e20171490. https://doi.org/10.1542/peds.2017-1490 10.1542/peds.2016-1493 27325637

154. Navas-Acien A. Francesconi K.A. Silbergeld E.K. Guallar E. Seafood intake and urine concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population Environ. Res. 2011 111 110 118 10.1016/j.envres.2010.10.009 21093857 PMC3073506

155. Flora S.J.S. Pachauri V. Chelation in metal intoxication Int. J. Environ. Res. Public Health 2010 7 2745 2788 10.3390/ijerph7072745 20717537 PMC2922724

156. Yiin L.-M. Lu S.-E. Sannoh S. Lim B.S. Rhoads G.G. Evaluation of cleaning methods applied in home environments after renovation and remodeling activities Environ. Res. 2004 96 156 162 10.1016/j.envres.2004.01.007 15325876

157. Sim C.-S. Kim Y. Lee H. Park C.-Y. Ham J.-O. Lee B.-K. Iron deficiency increases blood lead levels in boys and pre-menarche girls surveyed in KNHANES 2010–2011 Environ. Res. 2014 130 1 6 10.1016/j.envres.2014.01.004 24502852

158. Ettinger A.S. Lamadrid-Figueroa H. Téllez-Rojo M.M. Mercado-García A. Peterson K.E. Schwartz J. Hu H. Hernández-Avila M. Effect of calcium supplementation on blood lead levels in pregnancy: A randomized placebo-controlled trial Environ. Health Perspect. 2009 117 26 31 10.1289/ehp.11868 19165383 PMC2627861

159. Jamieson J.A. Taylor C.G. Weiler H.A. Marginal Zinc Deficiency Exacerbates Bone Lead Accumulation and High Dietary Zinc Attenuates Lead Accumulation at the Expense of Bone Density in Growing Rats Toxicol. Sci. 2006 92 286 294 10.1093/toxsci/kfj201 16624848

160. Gray P.J. Conklin S.D. Todorov T.I. Kasko S.M. Cooking rice in excess water reduces both arsenic and enriched vitamins in the cooked grain Food Addit. Contam. Part A 2016 33 78 85 10.1080/19440049.2015.1103906 26515534

161. Mortensen M.E. Wong L.-Y. Osterloh J.D. Smoking status and urine cadmium above levels associated with subclinical renal effects in U.S. adults without chronic kidney disease Int. J. Hyg. Environ. Health 2011 214 305 310 10.1016/j.ijheh.2011.03.004 21555245

162. Lai M.W. Boyer E.W. Kleinman M.E. Rodig N.M. Ewald M.B. Acute Arsenic Poisoning in Two Siblings Pediatrics 2005 116 249 257 10.1542/peds.2004-1957 15995066

163. Shannon M.W. Borron S.W. Burns M.J. Emergency Management of Poisoning Haddad and Winchester’s Clinical Management of Poisoning and Drug Overdose Elsevier Amsterdam, The Netherlands 2007 13 61 10.1016/B978-0-7216-0693-4.50007-4

164. Brown M.J. Role of Chelation During Pregnancy in the Lead Poisoned Patient J. Med. Toxicol. 2013 9 344 346 10.1007/s13181-013-0348-1 24243290 PMC3846981

165. Rosado J.L. López P. Kordas K. García-Vargas G. Ronquillo D. Alatorre J. Stoltzfus R.J. Iron and/or Zinc Supplementation Did Not Reduce Blood Lead Concentrations in Children in a Randomized, Placebo-Controlled Trial J. Nutr. 2006 136 2378 2383 10.1093/jn/136.9.2378 16920858

166. Rand M.D. Caito S.W. Variation in the biological half-life of methylmercury in humans: Methods, measurements and meaning Biochim. Biophys. Acta BBA—Gen. Subj. 2019 1863 129301 10.1016/j.bbagen.2019.02.003 30742954

167. Kirk L.E. Jørgensen J.S. Nielsen F. Grandjean P. Public health benefits of hair-mercury analysis and dietary advice in lowering methylmercury exposure in pregnant women Scand. J. Public Health 2017 45 444 451 10.1177/1403494816689310 28381203

168. McKay C.A. Role of chelation in the treatment of lead poisoning: Discussion of the Treatment of Lead-Exposed Children Trial (TLC) J. Med. Toxicol. 2013 9 339 343 10.1007/s13181-013-0341-8 24178899 PMC3846968

169. Rogan W.J. Dietrich K.N. Ware J.H. Dockery D.W. Salganik M. Radcliffe J. Jones R.L. Ragan N.B. Chisolm J.J. Rhoads G.G. The Effect of Chelation Therapy with Succimer on Neuropsychological Development in Children Exposed to Lead N. Engl. J. Med. 2001 344 1421 1426 10.1056/NEJM200105103441902 11346806

170. Kosnett M.J. The role of chelation in the treatment of arsenic and mercury poisoning J. Med. Toxicol. 2013 9 347 354 10.1007/s13181-013-0344-5 24178900 PMC3846971

171. Glotzer D.E. Freedberg K.A. Bauchner H. Management of Childhood Lead Poisoning: Clinical Impact and Cost-Effectiveness Med. Decis. Mak. 1995 15 13 23 10.1177/0272989X9501500104 7898292

172. Attina T.M. Trasande L. Economic Costs of Childhood Lead Exposure in Low- and Middle-Income Countries Environ. Health Perspect. 2013 121 1097 1102 10.1289/ehp.1206424 23797342 PMC3764081

173. Gould E. Childhood Lead Poisoning: Conservative Estimates of the Social and Economic Benefits of Lead Hazard Control Environ. Health Perspect. 2009 117 1162 1167 10.1289/ehp.0800408 19654928 PMC2717145

174. Pichery C. Bellanger M. Zmirou-Navier D. Glorennec P. Hartemann P. Grandjean P. Childhood lead exposure in France: Benefit estimation and partial cost-benefit analysis of lead hazard control Environ. Health 2011 10 44 10.1186/1476-069X-10-44 21599937 PMC3123267

175. Ericson B. Caravanos J. Depratt C. Santos C. Cabral M.G. Fuller R. Taylor M.P. Cost Effectiveness of Environmental Lead Risk Mitigation in Low- and Middle-Income Countries GeoHealth 2018 2 87 101 10.1002/2017GH000109 32159011 PMC7007121

176. Wilson J. Pivetz T. Ashley P. Jacobs D. Strauss W. Menkedick J. Dixon S. Tsai H.-C. Brown V. Friedman W. Evaluation of HUD-funded lead hazard control treatments at 6 years post-intervention Environ. Res. 2006 102 237 248 10.1016/j.envres.2006.04.007 16740256

177. Murray B. Streitz M.J. Hilliard M. Maddry J.K. Evaluation of an Electronic Dosing Calculator to Reduce Pediatric Medication Errors Clin. Pediatr. 2019 58 413 416 10.1177/0009922818821871 30616392

178. Dart R.C. Borron S.W. Caravati E.M. Cobaugh D.J. Curry S.C. Falk J.L. Goldfrank L. Gorman S.E. Groft S. Heard K. Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care Ann. Emerg. Med. 2009 54 386 394.e1 10.1016/j.annemergmed.2009.01.023 19406507

179. McKay C.A. Editorial: Use and Misuse of Metal Chelation Therapy J. Med. Toxicol. 2013 9 301 302 10.1007/s13181-013-0349-0 24178901 PMC3846977

180. Kennedy F. Absolom K. Clayton B. Rogers Z. Gordon K. O’Connell Francischetto E. Blazeby J.M. Brown J. Velikova G. Electronic Patient Reporting of Adverse Events and Quality of Life: A Prospective Feasibility Study in General Oncology JCO Oncol. Pract. 2021 17 e386 e396 10.1200/OP.20.00118 32853122 PMC8202059

181. Birkhead G.S. Klompas M. Shah N.R. Uses of Electronic Health Records for Public Health Surveillance to Advance Public Health Annu. Rev. Public Health 2015 36 345 359 10.1146/annurev-publhealth-031914-122747 25581157

182. Stiell I.G. Bennett C. Implementation of Clinical Decision Rules in the Emergency Department Acad. Emerg. Med. 2007 14 955 959 10.1111/j.1553-2712.2007.tb02372.x 17923717

183. Pak A. Robertson S.T. Nguyen B.H. Hodgson T. Sullivan C. Burton-Jones A. Mixed methods evaluation of a clinical decision support system to reduce variation in healthcare Npj Digit. Med. 2025 8 781 10.1038/s41746-025-02141-9 41353275 PMC12739111

184. Guo J.J. Pandey S. Doyle J. Bian B. Lis Y. Raisch D.W. A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group Value Health 2010 13 657 666 10.1111/j.1524-4733.2010.00725.x 20412543

185. Ettinger A.S. Leonard M.L. Mason J. CDC’s Lead Poisoning Prevention Program: A Long-standing Responsibility and Commitment to Protect Children From Lead Exposure J. Public Health Manag. Pract. 2019 25 S5 S12 10.1097/PHH.0000000000000868 PMC6320665 30507764

186. Lanphear B.P. Hornung R. Khoury J. Yolton K. Baghurst P. Bellinger D.C. Canfield R.L. Dietrich K.N. Bornschein R. Greene T. Low-Level Environmental Lead Exposure and Children’s Intellectual Function: An International Pooled Analysis Environ. Health Perspect. 2005 113 894 899 Erratum in Environ. Health Perspect. 2019 , 127 , 99001 10.1289/ehp.7688 16002379 PMC1257652

187. Inns R.H. Rice P. Bright J.E. Marrs T.C. Evaluation of the Efficacy of Dimercapto Chelating Agents for the Treatment of Systemic Organic Arsenic Poisoning in Rabbits Hum. Exp. Toxicol. 1990 9 215 220 10.1177/096032719000900403 2167707

188. Bernhoft R.A. Cadmium Toxicity and Treatment Sci. World J. 2013 2013 394652 10.1155/2013/394652 23844395 PMC3686085

189. Mjos K.D. Orvig C. Metallodrugs in Medicinal Inorganic Chemistry Chem. Rev. 2014 114 4540 4563 10.1021/cr400460s 24456146

190. Liu G. Garrett M.R. Men P. Zhu X. Perry G. Smith M.A. Nanoparticle and other metal chelation therapeutics in Alzheimer disease Biochim. Biophys. Acta BBA—Mol. Basis Dis. 2005 1741 246 252 10.1016/j.bbadis.2005.06.006 16051470

191. Yantasee W. Warner C.L. Sangvanich T. Addleman R.S. Carter T.G. Wiacek R.J. Fryxell G.E. Timchalk C. Warner M.G. Removal of Heavy Metals from Aqueous Systems with Thiol Functionalized Superparamagnetic Nanoparticles Environ. Sci. Technol. 2007 41 5114 5119 10.1021/es0705238 17711232

192. Yu X. Liu C. Guo Y. Deng T. Speciation Analysis of Trace Arsenic, Mercury, Selenium and Antimony in Environmental and Biological Samples Based on Hyphenated Techniques Molecules 2019 24 926 10.3390/molecules24050926 30866421 PMC6429259

193. Jia Z. Wang X. Wei X. Zhao G. Foster K.W. Qiu F. Gao Y. Yuan F. Yu F. Thiele G.M. Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects ACS Nano 2018 12 7663 7681 10.1021/acsnano.8b01249 29965725 PMC6117746

194. Hock N. Racaniello G.F. Aspinall S. Denora N. Khutoryanskiy V.V. Bernkop-Schnürch A. Thiolated Nanoparticles for Biomedical Applications: Mimicking the Workhorses of Our Body Adv. Sci. 2022 9 2102451 10.1002/advs.202102451 PMC8728822 34773391

195. Liu L. Wang J. Metal Release from and Sequestration by Metallothioneins Monitored by Electrochemistry and SPR Curr. Pharm. Biotechnol. 2011 12 847 852 10.2174/138920111795470886 21446906

196. Barkay T. Gu B. Demethylation—The Other Side of the Mercury Methylation Coin: A Critical Review ACS Environ. Au 2022 2 77 97 10.1021/acsenvironau.1c00022 37101582 PMC10114901

197. Hou R. Jin X. Feng J. Xue J. Chen C. Zou Y. Xu X. Yu K. Qian P.-Y. Zhang W. Deciphering the universal role of gut microbiota in pollutant transformation ISME J. 2025 19 wraf215 10.1093/ismejo/wraf215 41025510 PMC12516962

198. Coe G.L. Krout I.N. Munro-Ehrlich M. Beamish C.R. Vorojeikina D. Colman D.R. Boyd E.J. Walk S.T. Rand M.D. Assessing the role of the gut microbiome in methylmercury demethylation and elimination in humans and gnotobiotic mice Arch. Toxicol. 2023 97 2399 2418 10.1007/s00204-023-03548-7 37392210 PMC10913183

199. Chen C.-H.S. Kuo T.-C. Kuo H.-C. Tseng Y.J. Kuo C.-H. Yuan T.-H. Chan C.-C. Metabolomics of Children and Adolescents Exposed to Industrial Carcinogenic Pollutants Environ. Sci. Technol. 2019 53 5454 5465 10.1021/acs.est.9b00392 30971086

200. Hsiao C.-Y. Gresham C. Marshall M.R. Treatment of lead and arsenic poisoning in anuric patients—A case report and narrative review of the literature BMC Nephrol. 2019 20 374 10.1186/s12882-019-1561-1 31623560 PMC6796459

201. Smith S.B. Wombolt D.G. Venkatesan R. Results of Hemodialysis & Hemoperfusion in the Treatment of Acute Arsenic Ingestion Clin. Exp. Dial. Apher. 1981 5 399 404 10.3109/08860228109076031 7341026

202. Gebremedhin K.H. Kahsay M.H. Wegahita N.K. Teklu T. Berhe B.A. Gebru A.G. Tesfay A.H. Asgedom A.G. Nanomaterial-based optical colorimetric sensors for rapid monitoring of inorganic arsenic species: A review Discov. Nano 2024 19 38 10.1186/s11671-024-03981-2 38421536 PMC10904709

203. Wu J. Cao M. Tong D. Finkelstein Z. Hoek E.M.V. A critical review of point-of-use drinking water treatment in the United States npj Clean Water 2021 4 40 Erratum in npj Clean Water 2022 , 5 , 13. https://doi.org/10.1038/s41545-022-00159-0 10.1038/s41545-021-00128-z

204. Tinggi U. Perkins A.V. Selenium Status: Its Interactions with Dietary Mercury Exposure and Implications in Human Health Nutrients 2022 14 5308 10.3390/nu14245308 36558469 PMC9785339

205. Cuvin-Aralar M.L.A. Furness R.W. Mercury and selenium interaction: A review Ecotoxicol. Environ. Saf. 1991 21 348 364 10.1016/0147-6513(91)90074-Y 1868791

206. Weerasundara L. Ok Y.-S. Bundschuh J. Selective removal of arsenic in water: A critical review Environ. Pollut. 2021 268 115668 10.1016/j.envpol.2020.115668 33017746

207. Taylor V. Goodale B. Raab A. Schwerdtle T. Reimer K. Conklin S. Karagas M.R. Francesconi K.A. Human exposure to organic arsenic species from seafood Sci. Total Environ. 2017 580 266 282 10.1016/j.scitotenv.2016.12.113 28024743 PMC5326596

208. Bartel-Steinbach M. Lermen D. Gwinner F. Schäfer M. Göen T. Conrad A. Weber T. Von Briesen H. Kolossa-Gehring M. Long-term monitoring of mercury in young German adults: Time trend analyses from the German Environmental Specimen Bank, 1995–2018 Environ. Res. 2022 207 112592 10.1016/j.envres.2021.112592 34973943

209. Satarug S. Vesey D.A. Buha Đorđević A. Use of Urinary β2-Microglobulin in the Assessment of the Health Risk from Environmental Cadmium Exposure Appl. Sci. 2025 15 11757 10.3390/app152111757

210. Deaths Associated with Hypocalcemia From Chelation Therapy—Texas, Pennsylvania, and Oregon, 2003–2005 JAMA 2006 295 2131 10.1001/jama.295.18.2131 16511441

211. Roels H.A. Hoet P. Lison D. Usefulness of Biomarkers of Exposure to Inorganic Mercury, Lead, or Cadmium in Controlling Occupational and Environmental Risks of Nephrotoxicity Ren. Fail. 1999 21 251 262 10.3109/08860229909085087 10416202

212. Pamphlett R. Doble P.A. Bishop D.P. The Prevalence of Inorganic Mercury in Human Kidneys Suggests a Role for Toxic Metals in Essential Hypertension Toxics 2021 9 67 10.3390/toxics9030067 33801008 PMC8004013

213. Hoet P. Haufroid V. Lison D. Heavy metal chelation tests: The misleading and hazardous promise Arch. Toxicol. 2020 94 2893 2896 10.1007/s00204-020-02847-7 32676730

214. Jacobs D.E. Environmental Health Disparities in Housing Am. J. Public Health 2011 101 S115 S122 10.2105/AJPH.2010.300058 21551378 PMC3222490

215. Korenstein D. Chimonas S. Barrow B. Keyhani S. Troy A. Lipitz-Snyderman A. Development of a Conceptual Map of Negative Consequences for Patients of Overuse of Medical Tests and Treatments JAMA Intern. Med. 2018 178 1401 10.1001/jamainternmed.2018.3573 30105371 PMC7505335

216. Friedman D.B. Toumey C. Porter D.E. Hong J. Scott G.I. Lead J.R. Communicating with the public about environmental health risks: A community-engaged approach to dialogue about metal speciation and toxicity Environ. Int. 2015 74 9 12 10.1016/j.envint.2014.09.015 25305416

217. Haines A. Perkins E. Evans E.A. McCabe R. Multidisciplinary team functioning and decision making within forensic mental health Ment. Health Rev. 2018 23 185 196 10.1108/MHRJ-01-2018-0001 30464703 PMC6201820

218. Taberna M. Gil Moncayo F. Jané-Salas E. Antonio M. Arribas L. Vilajosana E. Peralvez Torres E. Mesía R. The Multidisciplinary Team (MDT) Approach and Quality of Care Front. Oncol. 2020 10 85 10.3389/fonc.2020.00085 32266126 PMC7100151

219. White R.E. Trbovich P.L. Easty A.C. Savage P. Trip K. Hyland S. Checking it twice: An evaluation of checklists for detecting medication errors at the bedside using a chemotherapy model Qual. Saf. Health Care 2010 19 562 567 Erratum in Qual. Saf. Health Care 2011 , 20 , 396 10.1136/qshc.2009.032862 20724398 PMC3002832

220. Powers E.M. Shiffman R.N. Melnick E.R. Hickner A. Sharifi M. Efficacy and unintended consequences of hard-stop alerts in electronic health record systems: A systematic review J. Am. Med. Inform. Assoc. 2018 25 1556 1566 10.1093/jamia/ocy112 30239810 PMC6915824

221. Berger S. Saut A.M. Berssaneti F.T. Using patient feedback to drive quality improvement in hospitals: A qualitative study BMJ Open 2020 10 e037641 10.1136/bmjopen-2020-037641 PMC7590344 33099495

222. Martinez-Morata I. Sobel M. Tellez-Plaza M. Navas-Acien A. Howe C.G. Sanchez T.R. A State-of-the-Science Review on Metal Biomarkers Curr. Environ. Health Rep. 2023 10 215 249 10.1007/s40572-023-00402-x 37337116 PMC10822714

223. Kosnett M.J. Chelation for Heavy Metals (Arsenic, Lead, and Mercury): Protective or Perilous? Clin. Pharmacol. Ther. 2010 88 412 415 10.1038/clpt.2010.132 20664538

224. Ruha A.-M. Recommendations for provoked challenge urine testing J. Med. Toxicol. 2013 9 318 325 10.1007/s13181-013-0350-7 24113861 PMC3846974

225. Gochfeld M. Burger J. Disproportionate exposures in environmental justice and other populations: The importance of outliers Am. J. Public Health 2011 101 S53 S63 10.2105/AJPH.2011.300121 21551384 PMC3222496

226. Adamkiewicz G. Zota A.R. Fabian M.P. Chahine T. Julien R. Spengler J.D. Levy J.I. Moving Environmental Justice Indoors: Understanding Structural Influences on Residential Exposure Patterns in Low-Income Communities Am. J. Public Health 2011 101 S238 S245 10.2105/AJPH.2011.300119 21836112 PMC3222513

227. Huber T. Brinkmann F. Lim S. Schröder C. Stekhoven D.J. Marti W.R. Egger R.R. Implementation of an IT-guided checklist to improve the quality of medication history records at hospital admission Int. J. Clin. Pharm. 2017 39 1312 1319 10.1007/s11096-017-0545-0 29082460 PMC5694519

228. Enticott J. Johnson A. Teede H. Learning health systems using data to drive healthcare improvement and impact: A systematic review BMC Health Serv. Res. 2021 21 200 10.1186/s12913-021-06215-8 33663508 PMC7932903

229. Platt J.E. Raj M. Wienroth M. An Analysis of the Learning Health System in Its First Decade in Practice: Scoping Review J. Med. Internet Res. 2020 22 e17026 10.2196/17026 32191214 PMC7118548